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A B S T R A C T
As of now, the Netherlands Journal of Medicine will become
freely accessible online. This represents a turning point
for the Journal as open access publishing provides instant
and universal availability of published work to any potential
reader, worldwide, completely free of subscriptions,
passwords and charges. This assures the widest possible
dissemination of scientific knowledge from the Journal
without boundaries of limited circulation or local avail-
ability of a hardcopy. We believe that by opening up we
are making research available to a much wider range of
readers than our print and subscription model would
have been able to achieve.
Now in its 47th year of publication, the Editorial board of
the Netherlands Journal of Medicine has decided to steer
the Journal into the electronic arena. As of now the content
of the Netherlands Journal of Medicine will be freely acces-
sible online. Immediately after publication of a paper, its
abstract will appear on PubMed, (www.pubmed.gov) and
from there the full text can immediately, without any
obstacles, be viewed and downloaded. This event marks
an important point in the history of the Journal and mate-
rialises our continuous efforts to make it better. 
Over the past three years, the Editorial board has invested
a great deal in improving the design and presentation of the
Journal.1,2 For example, probably one of the most tangible
enhancements of the Journal is its art cover. We adopted
the art cover because we believe that this promotes the
visibility of the Journal, and gives the Journal its own
personality. On the other hand, we have worked hard to
improve its content and have attracted high-quality manu-
scripts from Dutch and foreign authors alike. As Editorial
board we have chosen to adopt an active role and this has
resulted in a steady increase in the number of high-calibre
manuscripts submitted. For a large part, the Journal’s
content mirrors the research efforts of members of the
Dutch Society of Internal Medicine and as such it provides
unique insight into the contemporary biomedical research in
our country. The Society has a vested interest in advancing
clinical research and has an interest in making information
as widely available as possible. The first interest of the
Editorial board lies with the reader and accordingly, our
mission statement indicates that the Journal also serves
as a platform for (Dutch) young clinical investigators. We
have instigated a yearly competition with prizes for the
best original article, review and case report in the Journal.3,4
We also started photo quizzes as an illustrative feature of
the Journal.5 We believe that this yearly contest positively
contributes to the increasing quality of the Journal.
Without any doubt, the hardcopy version of the Journal
appeals to many of us. Most readers have indicated that
they like the physical appearance and enjoy browsing
through the pages to find snippets of knowledge that are
useful to them. Although this is important to us, we must
recognise that electronic journals offer readers a particular
ease of access. Indeed, with open access publishing, many
interests seem aligned, because we get what we want:
both speed of publication and free access to important
new findings for readers. Ideally, an electronic platform
allows readers to work across different journals, find
exactly where certain ideas are being discussed, or move
readily from citation to source. 
© 2005 Van Zuiden Communications B.V. All rights reserved.
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In order to provide open access the Editorial board went
for a two-step strategy. First, we noted that it could take
four to six months after the publication of a manuscript
in the Journal before its citation was listed on the PubMed
website (www.pubmed.gov). This was bothersome because
most researchers take PubMed as an entry point for a
literature search. Consequently, scientific knowledge
from the Journal that was readily available only reached the
scientific community some six months after publication.
In close collaboration with the publisher of the Journal
we have now closed the electronic gap, and papers are
now instantly picked up by PubMed. 
As an important second step, the Netherlands Journal of
Medicine has adopted a dual-mode open access model
which publishes an immediate and complete edition of
its subscription-based print version online. The full text
version was already directly available for members at
the website of the Dutch Society of Internal Medicine
(www.internisten.nl). From this issue onwards, it will be
possible to access the full text version directly from the
PubMed website. Each abstract on PubMed will be
accompanied by the Netherlands Journal of Medicine logo and
by clicking it, the full text of the paper can be downloaded
as an Adobe Portable Document Format version. We believe
that by opening up we are making research available to
a much wider range of readers than our print and sub-
scription model would have been able to achieve. We are
now able to disseminate important clinical knowledge not
bound by boundaries of circulation or by local availability
of a hardcopy. 
For the near future we foresee that open access will bring
some benefits. We are convinced that our Journal will
become more attractive to authors who want their results
to be read and applied widely. We expect that, in line with
experiences with other Journals, our efforts will not only
result in a upward trend in manuscript submissions, but
that these will also have a positive effect on the quality of
the submissions. There is evidence available which indicates
that free online papers have more impact than those
published in conventional print-only journals. Actually,
free online articles are cited earlier and more frequently
because they are more easily available.6
As a final step we envisage the implementation of an online
submission system. This tool allows electronic submission,
aids in the editorial workflow and permits online peer
review. We hope that this will enhance the efficiency of the
editorial processing of manuscripts and, more importantly,
will decrease time between submission and publication. 
We think that the future is ours, as publication in the
Journal assures wide and immediate dissemination.
Finally, let us thank those of you who read, submit and
review the Netherlands Journal of Medicine papers. You
make the journal what it is today and the Netherlands
Journal of Medicine is not our journal so much as yours.
As we are continuously working to improve accessibility
and quality of the Journal, we welcome your advice and
encourage you to send us your comments.
R E F E R E N C E S
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the Netherlands Journal of Medicine? Neth J Med 2003;61:99.
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2005;63:1.
3. Anonymous. The Netherlands Journal of Medicine awards for best original
article, case report and review. Neth J Med 2004;62:176.
4. Anonymous. Awards for best articles published in the Netherlands
Journal of Medicine in 2004. Neth J Med 2005;63:236 
5. Editorial board. Submit your case as a photo quiz! Neth J Med 2005;63:241.
6. Lawrence S. Free online availability substantially increases a paper’s
impact. Nature 2001;411:521.
J U L Y - A U G U S T  2 0 0 5 ,  V O L .  6 3 ,  N O .  7
Drenth. NJM: Open internet access.
240
The Netherlands Journal of Medicine has a fine tradition in
publishing articles for the Photo Quiz series. The quintes-
sence of a good Photo Quiz is the presentation of a case
that challenges the reader to make the diagnosis from
visual clues in the accompanying image. Sometimes they
illustrate an unusual disorder1-3 or highlight a remarkable
symptom or unusual presentation of an otherwise com-
mon disorder.4-6 In either case they should be instructive
and entice the reader to think about the possible diagnosis.
The question section may state the history of the case and
note the findings and the outcome, but it should not
divulge the diagnosis. Ideally, this should be accompanied
by no more than three high-quality figures with arrows
marking their key elements. The question should be
written in a single paragraph. The answer should give the
diagnosis and outline the key teaching points. We think
that these clinical cases in photo quiz form keep the
Journal lively and interesting. The Editorial board of the
Netherlands Journal of Medicine welcomes submission of
photographs and material to the Photo Quiz series.
R E F E R E N C E S
1. Eulderink F. A man with pancytopenia and liver complications. Neth J
Med 2004;62(1):22,27.
2. Bodar EJ, Simon A, van der Hilst JC, van Deuren M. Two patients with
recurrent fever and wine red discolouration of the eyelids. Neth J Med
2004;62(4):119-20,139.
3. Netea RT, Erceg A, Pieters G, Hermus AR. A patient with long-standing
skin lesions. Necrolytic migratory erythema. Neth J Med
2004;62(11):453,462.
4. Smit W, Reekers J, Schultz MJ. Malaise, anorexia, progressive limb pare-
sis and multiple defects in the kidneys. Neth J Med 2005;63(1):38,40.
5. Jansen HJ, Haerkens-Arends H, Vervoort G. A patient with dyspnoea,
subfebrile temperature and electrocardiographic abnormalities. Neth J
Med 2005;63(3):111,118.
6. Braam RL, Gaillard CA, Ike BW, Hagen EC. A case of multiple aortic
thrombi. Neth J Med 2004;62(8):304,306.
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Submit your case as a photo quiz!
Editorial board, the Netherlands Journal of Medicine
Department of Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, 
the Netherlands, tel.: +31 (0)24-361 04 59, fax: +31 (0)24-354 17 34, e-mail: g.derksen@aig.umcn.nl
E R R A T U M
The review ‘Nonalcoholic steatohepatitis’ by P.L.M. Jansen published in Neth J Med 2004;62(7):217-24 has also
been inadvertently published in Eur J Gastroenterol Hepatol 2004;16(11):1079-85. The author apologises for this error.
A B S T R A C T
The case report on cotrimoxazole-induced pancreatitis by
Versleijen et al. deals with the assessment of the probability
that cotrimoxazole induced the acute pancreatitis: a causality
assessment. In this editorial, we comment on this assess-
ment from a clinical, pharmacological and epidemiological
perspective. Moreover, the consequences of the results of
the assessment are discussed.
K E Y W O R D S
Adverse drug reaction reporting systems, drug effects,
pancreatitis, trimethoprim-sulphamethoxazole combination
The case report by Versleijen et al. on cotrimoxazole-induced
pancreatitis deals with several important issues on drug
safety and causality assessment.1 An adverse drug reaction
(ADR) is ‘A response to a drug which is noxious and
unintended, and which occurs at doses normally used in
man for the prophylaxis, diagnosis, or therapy of disease,
or for the modification of physiological function’.2 The
wording ‘a response to a drug’ raises the question on
causality: to what extent is the adverse event caused by the
use of the drug? The answer to this question, reflecting
causality assessment, requires a multidisciplinary approach
from a clinical, pharmacological and epidemiological
perspective.
From a clinical point of view, the temporal relationship
between the use of sulphamethoxazole and the diagnosis
of acute pancreatitis supports a causal relationship. The
previous episode with similar epigastric pain during
cotrimoxazole therapy, however, challenges causality,
since recovery during ongoing use of cotrimoxazole is
not very likely. 
Another clinical aspect may be that a positive rechallenge
strongly supports causality. However, pancreatitis may be
a recurrent disease, and the recurrence of pancreatitis
may be coincidentally related with the readministration of
cotrimoxazole. The reason for the rechallenge, despite the
strong suspicion that cotrimoxazole had caused an acute
pancreatitis, raises questions. Were the physicians involved
not aware of the suspicion, or was it an intended rechallenge
due to the lack of an alternative antibiotic therapy? 
From a pharmacological point of view, we agree with the
authors that no pharmacologically plausible link exists
between cotrimoxazole and pancreatitis. This implies that
the pancreatitis is facilitated by traits of the patient and
not by (known) pharmacological traits of the drug. Such
patient-related ADRs are called type B reactions and char-
acterised by the lack of a dose-effect relationship, very low
incidence but usually severe in nature, such as anaphylactic
reactions.3 Another pharmacological issue is that
trimethoprim and sulphamethoxazole both inhibit
cytochrome P450 isoenzymes, such as 2C8 and 2C9.4,5 If
concomitant medication had been involved, such inhibi-
tion could have caused an increase in serum levels of co-
medications that are metabolised by these enzymes. 
From an epidemiological point of view, causality assessment
involves the use of (pharmacovigilance) databases. In
general the Netherlands Pharmacovigilance Centre Lareb
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Is this reaction caused by this drug? 
W.L. Diemont†
Netherlands Pharmacovigilance Centre Lareb, Goudsbloemvallei 7, 5237 MH ’s-Hertogenbosch, 
the Netherlands, tel.: +31 (0)73-646 97 00, fax: +31 (0)73-642 64 36
usually uses the pharmacovigilance database of the WHO
collaborating centre in Uppsala, Sweden, involving spon-
taneous reporting systems of more than 75 countries and
with more than 3 million reports. The association between
trimethoprim and/or sulphamethoxazole and pancreatitis
has not been reported statistically more or less frequently
than all the other associations in the entire database
(reporting odds ratio 0.88 (CI 95: 0.73-1.02)). This implies
that all over the world reporters of ADRs have an ‘average’
concern about this association as compared with their
concern about all other reported associations. 
Similar calculations could be made in the database with
regard to the suggestion by the authors that ulphonamide
hypersensitivity could be involved in the described associa-
tion. Nevertheless, it should be emphasised that such
calculations do not prove causality but express the concerns
of reporters of ADRs. Moreover, epidemiological studies
in such databases require a proper assessment of quality
and completeness of the involved reports, as illustrated
by a study on drug-induced acute pancreatitis in the
Netherlands.6 In this series, the time between the first
intake of the suspect drug and the onset of acute pan-
creatitis varies between four hours (jectrolan as contrast
agent during an endoscopic retrograde
cholangiopancreatography (ERCP)) and two years (capto-
pril), but the median latency time was about 15 days. This
challenges the causal relationship in the described case
report because of its latency period of many years.
Besides these three aspects, other sources may support
causality as well. The presence of pancreatitis in the
summary of product characteristics (SPC) of the involved
drugs, available via www.cbg-meb.nl > medicines data
bank,7 at least implies that the causality of the association
was worth mentioning. The SPCs of trimethoprim does
not mention pancreatitis as ADR, in contrast to the SPCs
of the combined formulation of trimethoprim with sul-
famethoxazole. Moreover, previous publications on asso-
ciations, as pointed out by the authors, support such an
association as well.
Concluding that the reported association between cotrimox-
azole and pancreatitis has sufficient body of evidence to
be considered as having a ‘probable’ or even ‘certain’
causal relationship,2 what should the consequence be for
clinical practice in this patient?
First, it should not be considered a reason to withhold
cotrimoxazole to a patient who needs it. Adverse effects of
type B seldom occur and are unpredictable. The database
of the Netherlands Pharmacovigilance Centre contains one
report (out of more than 50,000 reports received between
1987 and 2005) of acute pancreatitis in association with
trimethoprim and none in association with cotrimoxazole.
The number of patients per year with a prescription with
a combination of sulphonamide and trimethoprim between
2000 and 2004 is about 179,556.8 Although, due to under-
reporting, no incidence figures should be calculated from
a spontaneous reporting system, one may conclude, also
based on the sparse reports in literature, that the described
association is rare. 
Second, the purpose of a published case report is to point
to the existence of a possible association between a drug
and an ADR. Its effect is not only limited to the association
that has been described. It is a constant reminder to the
physician that the existence of a possible ADR should be
part of every differential diagnosis. Patients, physicians,
dentists and pharmacists should be informed about this
type B ADR, since unintended re-exposure may have a
dramatic sequel. An intended re-exposure, e.g. due to the
lack of alternative medications with a vital indication,
should be done only under close medical supervision
under well-equipped conditions. 
Finally, the case report is a trigger to remind physicians
treating a patient with acute pancreatitis that drugs may
be involved in the aetiology and should be withhold as
much as possible.
N O T E
Willem L. Diemont unexpectedly died on 25 June 2005 in
Berlin while on his way to a clinical pharmacology congress
in Poznan, Poland. Willem Diemont was a specialist in
internal medicine and head of the unit Adverse Event
Notifications of the Netherlands Pharmacovigilance Centre
Lareb, which he joined in 1997. 
Correspondence according to this editorial can be mailed
to E.P. van Puijenbroek, e-mail: e.vanpuijenbroek@lareb.nl.
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Background: It has been suggested that normal concentra-
tions of biogenic amines and ‘histamine-releasing foods’
may exacerbate symptoms in mastocytosis. The purpose
of this study was to look for scientific evidence in the
literature on diets restricted in biogenic amines and hista-
mine-releasing foods in the treatment of mastocytosis. 
Methods: Medline (1966 to 2004), Cinahl (1982 to 2004)
and the Cochraine Library were searched for double-blind
placebo-controlled food challenge (DBPCFC) studies with
biogenic amines and/or histamine-releasing foods in
mastocytosis. 
Results: No studies employing DBPCFC with dietary
biogenic amines or histamine-releasing foods in masto-
cytosis were found. Only a few in vitro studies in other
diseases, animal studies and studies in humans in which
histamine-releasing agents were incubated directly with
duodenal tissues were found. One case was reported of
severe adverse reactions to alcohol in mastocytosis,
objectified by an open challenge.
Conclusion: Despite the widespread belief that biogenic
amines and histamine-releasing foods may cause allergy-like,
non-IgE-mediated symptoms in certain patients, the role of
diets restricted in biogenic amines and histamine-releasing
foods in the treatment of mastosytosis remains hypothetical
but worthy of further investigation. There is some evidence
for adverse reactions to alcohol in mastocytosis.
K E Y W O R D S
Adverse reactions, biogenic amines, double-blind placebo-
controlled food challenge, histamine-releasing foods,
mastocytosis
I N T R O D U C T I O N
Mastocytosis is an uncommon disorder characterised by
the accumulation of mast cells in various tissues including
bone marrow in the systemic form of the disease. The
essential role of mast cells in allergic diseases was recognised
a long time ago but the physiological role of mast cells is
still unclear. However, there is substantial evidence that mast
cells may play a key role in acquired and innate immune
responses in host defences against micro-organisms1,2 and
in wound healing and angiogenesis.3 Besides the well-
known triggering of degranulation of mast cell cells by
crosslinking of the FcRI receptor by specific allergens,
several other stimuli such as neuropeptides (substance P),
complement factors (C3a, C5a), lipoproteins, adenosine
and superoxides may activate mast cells.3
It has been suggested that foods containing high but
nontoxic levels of biogenic amines and the ‘histamine-
releasing foods’ may exacerbate symptoms in mastocytosis.
Alcohol is also considered to be a triggering factor in
mast cell degranulation.4 Therefore, it has been suggested
that diets restricted in biogenic amines or histamine-
releasing foods may be beneficial for some patients with
systemic mastocytosis. However, many authorities do not
mention diet intervention as a common therapeutic
measure,5 whereas others suggest certain foods to be a
possible trigger, but only in certain patients.4
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R E V I E W
Mastocytosis and adverse reactions to biogenic
amines and histamine-releasing foods: 
what is the evidence?
B.J. Vlieg-Boerstra1,2*, S. van der Heide2, J.N.G. Oude Elberink2, 
J.C. Kluin-Nelemans3, A.E.J. Dubois1,2
1Beatrix Children’s Hospital and Departments of 2Allergology and 3Haematology, University Medical
Centre Groningen, the Netherlands, *corresponding author
The purpose of this study was to verify in the literature if
there is any evidence for the putative beneficial effects of
elimination diets restricted in biogenic amines or histamine-
releasing foods. 
Biogenic amines
Biogenic amines are normal constituents of many foods.
These low-molecular-weight organic bases are formed in
plants and animals, and also endogenously in the human
body. Biogenic amines arise in foods by enzymatic decar-
boxylation of free amino acids.6 Biogenic amines are divided
into monoamines, such as tyramine, serotonin, phenyl-
ethylamine, dopamine, epinephrine and norepinephrine,
and diamines, such as histamine, cadaverine and putrescine.
Adverse reactions to foods are most frequently reported in
foods containing high levels of tyramine and histamine,
which is referred to as histamine poisoning or scrombroid
poisoning.7 This intoxication is caused by high levels of
histamine, for example in spoiled scrombroid fish, such
as tuna and mackerel. Tyramine and histamine are formed
by decarboxylation of tyrosine and histidine respectively,
both amino acids.6,7
Endogenously synthesised biogenic amines fulfil important
metabolic functions in the body. Histamine plays a role
in normal and abnormal biological processes, including
vasodilatation, gastric acid secretion and allergic reactions.
In contrast to histamine, tyramine is vasoconstrictive and
may cause an increase in blood pressure. 
Generally, monoamine oxidases (MAO A and MAO B) and
diamine oxidase (DAO) play a major role in the catabolism
of monoamines and diamines, respectively. These enzymes
are located in the gastrointestinal tract, and also in the
liver, lung, platelets, spleen and kidneys. These enzymes
prevent the absorption of unmetabolised biogenic amines
into the circulation. The metabolism of histamine is depicted
in figure 1. There are two main enzymatic pathways:
• Histamine is converted by histamine methyltransferase
(HMT) to methylhistamine (MH), and subsequently
metabolised by MAO to methylimidazole acetic acid
(MIMA) or 
• histamine is deaminated by DAO to imidazole acetic
acid (IAA).8
Dietary biogenic amines are especially found in aged and
fermented food, and in foods containing relatively high
amounts of free amino acids.9 Most notably, ripened cheese,
fermented meat, smoked and tinned fish, sauerkraut and
fermented yeast and fermented soy products usually
contain significant amounts of histamine. Concentrations
of histamine may vary considerably and a daily dietary
intake of histamine of 100 to 200 mg can easily be reached,
depending on the foods chosen. In tables 1 and 2, the
Vlieg-Boerstra, et al. Mastocytosis and adverse reactions to food.
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Table 1 Foods rich in histamine
Food categories Mg histamine/100 gram Mg histamine/serving
Cheese: Gouda, Cheddar, Danish Bleu, Emmenthaler, goats cheese, 3.3-171 0.7-35 (20 gram)
Gorgonzola, Mascarpone, Parmesan
Meat: fermented meat, hare, (dry) sausage, raw ham 3.0- 27 0.6-5.5 (20 gram)
Fish: herring, smoked mackerel, tinned fish (sardines), tuna fish, 0.8-16.5 0.6-11.5 (70 gram)
anchovy products 95-344 9.5-34 (10 gram)
Vegetables: egg plant, spinach, sauerkraut 2.5-11.5 5-23 (200 gram)
Alcoholics: beer and wine 0.6-1.6 0.6-1.6 (100 ml)
1.2-2.2 (200 ml)
Fermented foods: Tamari, marmite, trassi, tempe 8.3-212 0.8-21 (10 gram)
Table 2 Foods rich in tyramine
Food categories Mg tyramine/100 gram Mg tyramine/serving
Cheese: most cheeses 5.0-152 1.0-31 (20 gram)
Chocolate 0.8 0.2 (25 gram)
Meat: fermented meat, hare, (dry) sausage, raw ham 8.5-56 1.7-11 (20 gram)
Fish: smoked fish, tinned fish (sardines, tuna), shrimps 2.5-12.9 1.8-9 (70 gram)
anchovy products 6.4-13 0.6-1.3 (10 gram)
Vegetables: egg plant, spinach, sauerkraut 6.1-16.5 12.2-33 (200 gram)
Alcoholics: beer and wine 0.5-3.6 0.5-3.6 (100 ml)
1.0-7.2 (200 ml)
Fermented foods: soy sauce, marmite, trassi, tempe 15-178 1.5-18 (10 gram)
respective amounts of histamine and tyramine in mg per
serving in food categories rich in biogenic amines are
shown. In table 3 some foods low in histamine in these
food categories are shown.
Histamine-releasing foods
Many foods or food components are considered to have
the capacity to release histamine directly from tissue mast
cells in the body.9 These foods are listed in table 4. 
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Figure 1 Metabolism of histidine and histamine8
DAO = diamine oxidase (or histaminase); IAA = imidazole acetic acid; HMT = histamine methyltransferase; MAO = monoamine oxidase; 
MH = methylhistamine; MIMA = methylimidiazole acetic acid.
M A T E R I A L S  A N D  M E T H O D S
Medline (1966-2004), Cinahl (1982-2004) and the
Cochraine Library were searched in the English and
German language for clinical studies on adverse reactions
to biogenic amines and histamine-releasing foods in
mastocytosis. Clinical studies were defined as studies
employing dietary elimination followed by DBPCFC studies
with biogenic amines or histamine-releasing foods in
human beings with suspected or confirmed mastocytosis.
For studies on biogenic amines the keywords (biogenic
amin* or histamin* or methylhistamin*) were combined
with (mastocytosis or systemic mastocytosis or mast cell
disease or urticaria pigmentosa) and (food or diet or
hypersens* or adverse or intolerant or intolerance or allerg*
or toxicity or nonIgE). For studies on histamine-releasing
effects of foods the keywords (histamine releas* or releas*)
were combined with (mastocytosis or systemic mastocytosis
or mast cell disease or urticaria pigmentosa) and (food or
diet or hypersens* or adverse or intolerant or intolerance
or allerg* or toxicity or nonIgE).
R E S U L T S  
No clinical studies employing DBPCFC were found on
(adverse) effects of dietary biogenic amines in mastocytosis,
or on (adverse) effects to histamine-releasing foods. Only
one study employing an open food challenge with histamine
rich foods was found.10 In this study Vidal and others
described a patient with a rare form of cutaneous masto-
cytosis (telangiectasia macularis eruptiva perstans) suspected
to suffer from adverse reaction to fish, but in whom open
food challenges with fresh crayfish, shrimp and tuna
were negative. 
Studies in human beings on the putative histamine-
releasing effects of foods are limited to reports of such
effects on ex vivo duodenal tissue performed by Moneret-
Vautrin and coworkers.11 They showed that incubating
duodenal biopsy material with various histamine-releasing
pharmacological agents, such as compound 48/80,
Concanavalin A, the calcium ionophore A 23187, and
anti-IgE resulted in increased nonspecific release of hista-
mine by duodenal mast cells. They demonstrated that in
subjects with non-IgE-mediated adverse reactions to food,
duodenal mucosal biopsies show massively degranulated
cells in sharp contrast to those seen in controls. 
According to these authors, these findings support the
hypothesis that the digestive mucosal mast cells may be
abnormally sensitive to histamine liberation in some
subjects.12 However, they showed no in vivo data to support
the relevance of these findings. In addition, we found no
clinical studies using oral challenge tests to support the
hypothesis for the histamine-releasing capacity of foods. 
Only a few in vitro studies and animal studies in other
diseases have demonstrated histamine-releasing effects
of foods or food components, but no literature on this
subject was found dating from the last two decades.
Schachter and Talesnik found in 1952 that egg white
releases histamine in nonsensitised animals when injected
intravenously.13 In this article the authors refer to unpub-
lished data by Schachter on histamine-releasing effects of
strawberries and to a publication on histamine liberation
by shellfish, published by WDM Paton in 1954 in J Physiol
1954;123:58P, and by E. Urbach in Allergy 1946, Heineman,
London. We were not able to obtain a copy of these old
articles to verify their conclusions. In some studies, it
was demonstrated in vitro that in both chronic urticaria
patients and controls, food additives were able to release
histamine from leucocytes.14,15 However, no differences
between patients and controls were found. Baenkler and
coworkers conducted in vitro tests with wheat, egg, milk
and fish on the mucosa of patients suffering from several
intestinal diseases, including patients suffering from food
intolerance and inflammatory diseases.16 In all these
patients skin tests with these foods were negative.
Significant differences were found in histamine-release
between patient groups. Surprisingly, the smallest amount
of histamine release was found in the food-intolerant
patients, the largest amount in the inflammatory group.
We could not find any study on histamine-releasing
effects of most of the foods suggested of having histamine-
releasing capacities, as shown in table 4.
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Table 3 Exceptions: Foods low in histamine
Food categories Mg histamine/100 gram
Cheese: Edam, Brie, Camembert, 0.0-0.3
Feta, Mozzarella
Fish: fresh/frozen fish (codfish, 0.0-0.1
salmon, sole, whiting, place, crab, 
mussels)
Chocolate 0.1
Fermented foods: tofu 0.1
Table 4 Foods with suggested histamine-releasing
capacities
Additives Alcohol Chocolate
Citrus fruit Crustaceans Egg white
Fish Liquorice Nuts
Papaya Peanuts Pineapple
Pork Spices Spinach
Strawberries Tomatoes
In one case, adverse effects to alcohol in mastocytosis
were reported. Bandmann et al. described a patient with
anaphylactic-like reactions to alcohol, objectified by open
challenge.17 This patient reacted to 20 ml of cognac with
flush, tachycardia, severe headache and diarrhoea.
D I S C U S S I O N
Despite the widespread belief that biogenic amines and
histamine-releasing foods may cause allergy-like, non-IgE-
mediated symptoms in certain patients, our literature
search failed to identify any clinical study in patients with
mastocytosis employing DBPCFC to demonstrate putative
adverse effects of these foods and food components. 
Several hypotheses have been formulated to explain such
putative adverse reactions to normal amounts of biogenic
amines, although these hypotheses have not been put
forward in relation to mastocytosis. Firstly, a decreased
level of DAO is said to be a cause of intolerance to biogenic
amines. Some studies showed a decreased level of DAO
in patients with atopic dermatitis and chronic urticaria.18-21
Secondly, inhibiting effects of substances on DAO,
MAO or HMT might be other causes for intolerance to
biogenic amines. Many inhibitors of MAO, DAO or HMT
in food have been identified.7 For example, other biogenic
amines such as tyramine might inhibit these enzymes and
could theoretically potentiate histamine intoxication.
Furthermore, there have been numerous reports on hyper-
tensive crises in patients using MAO-inhibiting drugs22
in combination with foods rich in tyramine. Remarkably,
there are no data available on the hazardous effect of
MAO-inhibiting drugs and histamine release in patients
with mastocytosis. Thirdly, the barrier disruptive hypothe-
sis has been described by Taylor.7 This hypothesis holds
that several potentiators might interfere with the protec-
tive function of intestinal mucin. These potentiators, such
as cadaverine and putrescine (other biogenic amines),
would bind to mucine and in this way facilitate an increased
absorption of histamine. There is a lack of evidence sup-
porting these putative mechanisms and no clinical studies
suggesting that these mechanisms might be operative. 
A recent literature survey from 1966 to 2001 by Jansen et al.
on adverse reactions to biogenic amines showed no sup-
portive evidence for the relation to migraine, headache or
wine intolerance. In relation to chronic urticaria no
methodologically sound studies were found.23 In one
DBPCFC study in healthy volunteers,24 symptoms such
as headache, dizziness and discomfort in 11 out of 54
challenges were found after 5 mg phenylethylamine, but
not after 25 mg histamine or 25 mg tyramine. 
There is no convincing evidence that patients with masto-
cytosis have increased releasability of mast cells as com-
pared with normal mast cells. It is generally thought that
symptoms resulting from mediator release are due to high
mast cell load,4,5 rather than to increased releasability.
Furthermore, there are no DBPCFC studies in human
beings supporting the widely held belief that foods
should have histamine-releasing capacity. The hypothesis
that foods may have a histamine-releasing capacity is
based on several older in vitro studies, animal studies in
other diseases demonstrating histamine-releasing effects
of foods, and on studies in which pharmacological sub-
stances were incubated directly with digestive tract mucosal
tissues. Thus, the normal digestive influences on foods
are eliminated and the significance of these findings is
doubtful. The Committee of Adverse Reactions to Foods
of the American Academy of Allergy and Immunology25
concluded in 1984 that the effects of such foods are
‘unproven’. Taken together, the theories on adverse reac-
tions to normal amounts of biogenic amines and the
histamine-releasing capacities of foods in patients with
mastocytosis are unproven. However, the persistence of
these theories on adverse reactions to biogenic amines
and the histamine-releasing capacity of foods suggest that
further investigation is necessary to confirm or reject the
putative effects of these food substances.
Adverse reactions to alcohol may be relevant in some
patients with mastocytosis, although the prevalence of
this phenomenon is unknown.17 The explanation for the
documented anaphylactic reaction to alcohol in masto-
cytosis can be found in similar metabolic pathways for
alcohol and histamine;5,26 alcohol and acetaldehyde inhibit
DAO, which results in elevated histamine levels.
Furthermore, acetaldehyde has shown to have a degranu-
lating and histamine-releasing effect on mast cells.26-28
Elevated concentrations of histamine metabolites are found
in patients with mastocytosis. Although measurement of
serum tryptase is currently being used in diagnosing
mastocytosis,4,5 in some centres the measurement of urinary
excretion of the histamine metabolites MIMA and MH is
used as an additional biochemical marker for mastocytosis.
These metabolites are formed endogenously, but also
dietary intake enhances the urinary excretion of these
amines.6-8,29 Furthermore, Keyzer and others found that a
diet high in protein (138 g) with exclusion of foods that may
be rich in histamine significantly enhances the amount of
MH.29 This is caused by high levels of tyramine in diets
rich in protein. Therefore, dietary restrictions in histamine
and protein intake before urinary sampling of histamine
metabolites are justified.
In conclusion, a review of the literature provided no sound
scientific support for beneficial effects of diets restricted
in biogenic amines and histamine-releasing foods in
patients with mastocytosis. Therefore, the role of these
diets in the treatment of mastocytosis remains hypothetical.
However, systematic studies have not been carried out
and further investigation is warranted. Such studies should
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confirm putative adverse effects of these foods and food
components by DBPCFC. Although there is little evidence
incriminating alcohol as a cause of adverse reactions in
patients with systemic mastocytosis, caution is probably
warranted until more studies have been done. 
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A B S T R A C T
Background: Obesity is characterised by insulin resistance
and by elevated levels of proinflammatory markers. We
investigated whether, in the absence of changes in glucose,
thiazolidinediones (TZDs) have anti-inflammatory effects
and whether improvement of insulin sensitivity correlates
with suppression of inflammatory markers.
Methods: We performed a randomised double-blind place-
bo-controlled crossover study with troglitazone (400 mg
daily for eight weeks) in 15 normoglycaemic obese subjects.
We measured plasma high-sensitivity C-reactive protein
(hsCRP), interleukin-6 (IL-6), leptin, tissue-type plas-
minogen activator (tPA), plasminogen activator inhibitor-1
(PAI-1) and tumour necrosis factor- (TNF-) after each
of the two treatment periods and in 13 age- and sex-matched
lean individuals.
Results: Obese subjects were insulin resistant (decreased
glucose infusion rate (GIR) during euglycaemic hyper-
insulinaemic clamp) and had higher plasma levels of hsCRP,
IL-6, leptin, tPA, and PAI-1 compared with lean subjects.
TNF- also tended to be higher. Troglitazone improved
insulin sensitivity (mean increase in whole body glucose
uptake 23.1 ± 10.5% (p=0.047)) and normalised plasma
concentrations of hsCRP, tPA and TNF-, whereas it did
not significantly change IL-6, leptin and PAI-1. Changes in
GIR did not correlate with changes in inflammatory markers.
Conclusion: Troglitazone induces suppression of some of
the inflammatory markers that are elevated in normogly-
caemic obese subjects. The suppression of inflammatory
markers, however, does not correlate with improvement
in insulin sensitivity, suggesting involvement of partially
differential mechanisms in these effects of TZDs.
K E Y W O R D S
Inflammation, insulin sensitivity, obesity, thiazolidinediones,
trial
I N T R O D U C T I O N
Insulin resistance, which is a common feature of obesity,
appears to be central to the pathogenesis of type 2 diabetes.1-3
Insulin resistance is hypothesised to develop in obesity
mainly as a result of adverse effects of elevated plasma
levels of free fatty acids (FFA).4,5 FFA or their metabolites
can impair insulin action and inhibit glucose transport
activity by stimulation of protein kinase C isoforms.
Furthermore, by increasing the level of oxidative stress,
FFA activate stress-sensitive signalling pathways such as
the nuclear transcription factor B (NFB) pathway, which
plays an important role in inflammation.6 In addition to
FFA, chemical messengers synthesised and secreted by
adipocytes, such as tumour necrosis factor- (TNF-) and
leptin, may influence insulin sensitivity.1,4
Recent studies have indeed confirmed a role for inflam-
mation in the pathogenesis of insulin resistance. Plasma
concentrations of the inflammatory mediators interleukin-6
(IL-6), TNF- and TNF-receptor and plasminogen activator
inhibitor-1 (PAI-1) were elevated in the obese.7-12 Moreover,
some markers of subclinical vascular inflammation, in
particular high-sensitivity C-reactive protein (hsCRP) and
IL-6, correlated with insulin sensitivity7,8,13,14 and were shown
to be powerful independent predictors of development of
type 2 diabetes.15,16
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O R I G I N A L  A R T I C L E
Anti-inflammatory effects of troglitazone in
nondiabetic obese subjects independent of
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Thiazolidinediones (TZDs), peroxisome proliferator-activated
receptor-gamma (PPAR-) agonists, improve insulin
sensitivity.17-19 PPAR- regulates the transcription and
expression of specific genes that affect fat in adipose tissue,
skeletal muscle and the liver.17 TZDs induce a redistribution
of fat out of skeletal muscle and liver into peripheral
adipocytes20-22 resulting in a sustained decrease in plasma
FFA23,24 and hence an improvement in insulin sensitivity
and a reduced activation of stress-sensitive signalling
pathways. Activation of PPAR- receptors may also
directly contribute to reduction of chronic subclinical
inflammation.25,26 Several studies have shown that TZDs
reduce NFB activation and decrease elevated levels of PAI-1
and hsCRP, but most of these studies were performed in
subjects with diabetes.27-31 However, it is uncertain whether
a decrease in plasma glucose levels contributes to the
decreases in inflammatory parameters. Therefore, we
investigated effects of troglitazone on plasma levels of
hsCRP, IL-6, leptin, tissue-type plasminogen activator
(tPA), PAI-1 and TNF- in nondiabetic obese subjects
characterised by insulin resistance.
M A T E R I A L S  A N D  M E T H O D S
Subjects
The study groups consisted of 15 obese and 13 lean nor-
motensive, healthy volunteers on no medication. Inclusion
criteria were age between 25 and 50 years, nonsmokers,
normal fasting glucose concentration, stable body weight,
and a body mass index (BMI) between 27 and 36 kg/m2
for the obese and between 19 and 25 kg/m2 for the lean.
All gave written informed consent. The experimental
protocol was approved by the hospital ethics committee.
Protocol
After inclusion, the obese subjects received either troglita-
zone (2x200 mg daily) or placebo for eight weeks in a
randomised double-blind crossover design. Participants
were strictly advised to maintain their weight and not to
change their diet. At the end of each of the two treatment
periods and after an overnight fast, 30 ml of blood was
collected in EDTA-containing tubes and plasma was isolated
by centrifugation at 4°C and stored in aliquots at -80°C.
Subsequently, a euglycaemic-hyperinsulinaemic clamp
(insulin [Actrapid; Novo-Nordisc], infusion rate 430 pmol
x m2x min-1 [60 mU/dl/min]) was performed for 120
minutes. Body weight, waist-hip measurements, ECG,
fat skinfold thickness, possible side effects, and serum
chemical and haematological profiles were determined as
a safety precaution. Between the treatment periods there
was a two-week washout phase. Compliance was monitored
by pill counts and amounted to over 90%.
Analytical measurements
Plasma glucose was measured by the glucose oxidation
method (Beckman Glucose Analyser 2; Beckman
Instruments, Fullerton, CA, USA). Plasma insulin was
measured with a double antibody radioimmunoassay
(interassay coefficient of variation 6.2%). FFAs (nonesterified
fatty acids, NEFAs) were analysed with an enzymatic method
(ACS-ACOD, NEFA C-kit; Waco, Neuss, Germany).
Cholesterol and triglycerides were determined by enzymatic
methods (Boehringer-Mannheim, Mannheim, Germany)
on a Hitachi 747 analyser (Hitachi, Tokyo, Japan).
HsCRP32 was measured by an ELISA from Kordia (Leiden,
the Netherlands); serum leptin by a RIA kit from Linco
Research Inc. (St. Louis, MO, USA); IL633 by the Pelikine
Compact human IL6 ELISA kit from CLB (Amsterdam,
the Netherlands); and TNF, tPA and PAI-1 were deter-
mined by specific ELISAs as described elsewhere.34
Statistical analysis
Data are presented as mean ± SE and evaluated by using
Student’s t-test for paired and unpaired data. Linear
regression analysis was performed to examine the relation-
ship between (changes in) variables. Significance was set
at a p value of less than 0.05. The computer programme
ASTUTE (Microsoft Ink, Redmond, WA, USA) was used
for the analysis.
R E S U L T S
Characteristics of the two study groups are presented in
table 1. The groups were properly matched for age and sex.
Fat percentage, waist-hip ratio, fasting plasma insulin,
triglycerides and NEFAs, but not fasting glucose and
cholesterol, were significantly higher in the obese than in
the lean control subjects. The obese had higher diastolic
blood pressure than the lean; no difference was seen for
systolic blood pressure. Compared with the values for
insulin sensitivity of lean subjects, the obese were clearly
insulin resistant: whole-body glucose uptake during
euglycaemic hyperinsulinaemic clamp was significantly
lower in the obese than in the lean control subjects.
Insulin sensitivity (i.e. glucose infusion rate (GIR) during
euglycaemic hyperinsulinaemic clamp) correlated strongly
with BMI (r=-0.67, n=26, p=0.0002).
Plasma levels of hsCRP, IL-6, leptin, tPA, and PAI-1 were
significantly higher in the obese compared with the lean
group (table 2). Plasma level of TNF- tended to be higher
in the obese subjects, but this difference did not attain
statistical significance (table 2). HsCRP, IL-6 and leptin
were strongly associated with BMI (r=0.53, 0.48, and
0.70, respectively) and with GIR (r=-0.51, -0.55, and -0.57,
respectively; figure 1). TPA was weakly associated with
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GIR (r=0.44) but not with BMI. TNF- was not associated
with GIR but correlated weakly with BMI (r=0.40). PAI-1
was not associated with GIR or BMI.
Troglitazone was well tolerated. No changes were observed
for body weight, plasma triglycerides, total cholesterol,
and fasting plasma glucose concentration (data not shown).
A nonsignificant decrease was observed for plasma NEFAs
(from 0.65 ± 0.08 to 0.48 ± 0.06 mmol/l, p=0.08). Fasting
insulin concentrations tended to decrease but remained
elevated compared with those in the lean control subjects
(data not shown). Insulin sensitivity improved, as evidenced
by increased whole-body glucose uptake during euglycaemic
hyperinsulinaemic clamp: mean percentage increase in whole
body glucose uptake amounted to 23.1 ± 10.5% (p=0.047).
During troglitazone treatment, plasma concentrations of
hsCRP, TNF- and tPA of the obese decreased significantly
(table 2). Consequently, after treatment these values were
not different from those of the lean control subjects.
Plasma levels of IL-6, leptin and PAI-1 in the obese did
not significantly change during troglitazone treatment
and remained elevated compared with the lean subjects.
Troglitazone-induced changes in hsCRP, TNF- and tPA
did not correlate with changes in GIR (data not shown). 
D I S C U S S I O N
In line with previous reports, we confirmed the presence
of a proinflammatory state in insulin-resistant obese
subjects,15,16,35 as levels of hsCRP, IL-6, leptin, tPA, and
PAI-1 were significantly higher in the obese than in the
lean. Moreover, levels of hsCRP, IL-6, and leptin inversely
correlated with insulin sensitivity. This is consistent with
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Table 1 Characteristics of study groups
Lean Obese P value
Number (m/f) 13 (7/6) 15 (9/6)
Age (year) 38.3 ± 2.1 37.4 ± 1.2 NS
BMI (kg/m2) 21.9 ± 0.6 31.7 ± 0.8 <0.001
Fat (%) 22.6 ± 1.7 35.8 ± 1.8 <0.001
Waist/hip 0.86 ± 0.02 1.01 ± 0.02 <0.001
Total cholesterol (mmol/l) 4.61 ± 0.27 4.91 ± 0.26 NS
Triglycerides (mmol/l) 0.82 ± 0.10 2.11 ± 0.59 0.05
NEFAs (mmol/l) 0.38 ± 0.05 0.65 ± 0.08 0.01
Glucose (mmol/l) 5.2 ± 0.1 5.5 ± 0.1 NS
Insulin (pmol/l) 40.9 ± 1.4 85.6 ± 2.1 <0.001
GIR (mol/kg/min) 53.9 ± 4.3 27.0 ± 2.9 <0.001
Systolic BP (mmHg) 118 ± 3 123 ± 3 NS
Diastolic BP (mmHg) 73 ± 4 82 ± 2 <0.05
BMI = body mass index; NEFAs = nonesterified fatty acids; GIR = glucose infusion rate; BP = blood pressure; NS = not significant.
Table 2 Plasma concentrations of markers of inflammation in lean subjects and in obese subjects treated with 
placebo or troglitazone
Lean (n=13) Obese (n=15)
Placebo* Troglitazone*/†
HsCRP (mg/l) 1.06 ± 0.32 4.53 ± 1.28‡ 2.23 ± 0.61ns/‡
TNF- (ng/l) 3.37 ± 0.39 4.54 ± 0.51ns 3.67 ± 0.49ns/§
IL-6 (ng/l) 1.08 ± 0.15 1.60 ± 0.13‡ 1.57 ± 0.19‡/ns
Leptin (g/l) 6.0 ± 1.4 17.2 ± 3.2§ 16.5 ± 3.3§/ns
tPA (g/l) 1.02 ± 0.10 1.58 ± 0.13§ 1.15 ± 0.12ns/§
PAI-1 (g/l) 9.2 ± 1.0 19.5 ± 3.0§ 17.2 ± 2.3§/ns
HsCRP = high-sensitivity C-reactive protein; TNF- = tumour necrosis factor-; IL-6 = interleukin 6; tPA = tissue-type plasminogen activator;
PAI-1 = plasminogen activator inhibitor-1. *T-test vs values of lean control subjects; †paired t-test vs values of placebo-treated obese subjects;
‡p<0.05; §p<0.01; ns = not significant.
the hypothesis that chronic subclinical inflammation is
involved in the pathogenesis of insulin resistance.16
The eight-week treatment with troglitazone normalised
plasma levels of hsCRP, TNF- and tPA in obesity but did
not affect levels of IL-6, leptin and PAI-1. Since the obese
were insulin resistant but did not have diabetes, the
observed troglitazone-induced changes in inflammatory
markers cannot be caused by changes in blood glucose
metabolism.36
Plasma TNF- was not significantly elevated in our obese,
insulin-resistant study group. Earlier reports on plasma
concentrations of TNF- in obesity are not uniform.
Whereas Hauner et al. observed normal plasma levels of
TNF- in obesity,10 others reported markedly elevated
plasma TNF- concentrations in obese subjects when
compared with lean controls.12 The latter suggested that
circulating TNF- in obesity reflects the level of expression
of TNF- message and protein synthesis in adipose tissue.12
However, recently, Kern et al. demonstrated that despite
markedly increased TNF- secretion from adipose tissue
in obesity, plasma levels of TNF- need not deviate from
normal.8 In their study it was the adipose-secreted form
of TNF- that displayed the strongest relationships with
obesity and insulin resistance. They and others suggested
that adipose tissue-derived TNF- and leptin (a messenger
molecule produced solely by adipose tissue) induce the
production of IL-6 and hsCRP, thus contributing to the
development of a proinflammatory state with increasing
body weight in obesity.37,38 The strong relationships that
we observed between BMI and insulin sensitivity and
plasma hsCRP, IL-6 and leptin but not plasma TNF-,
are in agreement with this hypothesis.
It was previously shown that in prediabetics, troglitazone
reduced plasma concentrations of hsCRP39 and rosiglita-
zone suppressed the generation of reactive oxygen species
by mononuclear cells ex vivo and reduced plasma hsCRP
and MCP-1.40 In both studies only nondiabetic obese
subjects (7 for troglitazone and 11 for rosiglitazone) and
no healthy lean controls were included. More recently,
other studies have also shown that rosiglitazone
decreased markers of inflammation and endothelial activa-
tion (CRP, PAI-1 and von Willebrand factor) in nondiabetic
subjects with stable coronary artery disease,41 hypertension,42
or metabolic syndrome.43 It is unclear whether these
decreases correlated with an improvement in insulin
sensitivity. Our study included 15 obese well-characterised
insulin-resistant subjects and 13 healthy lean controls and
had a double-blind placebo-controlled crossover design.
We have demonstrated that plasma levels of all studied
inflammatory parameters are elevated in obesity and that
some of them normalise during troglitazone treatment.
Thus, there was a distinct though selective beneficial
effect of troglitazone on the inflammatory status. To our
knowledge, effects of TZDs on tPA and leptin have not
been investigated before and IL-6 has not been previously
studied in prediabetics. In our study, as with rosiglitazone
in patients with type 2 diabetes,27 troglitazone did not
significantly change plasma levels of IL-6. Furthermore,
the observed decreases in the levels of the inflammatory
proteins hsCRP, TNF- and tPA did not correlate with
troglitazone-induced improvement in insulin sensitivity.
In addition, despite some improvement in insulin sensi-
tivity by troglitazone, the obese group remained quite
insulin resistant as compared with the lean group. In
contrast, troglitazone almost normalised the levels of the
proinflammatory cytokines. Together, these observations
suggest that troglitazone exerts its action, at least partially,
via different pathways. Troglitazone may affect inflammation
directly by activation of PPAR- present on monocytes,
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Figure 1 Association of insulin sensitivity with plasma
levels of leptin, interleukin-6 (IL-6) and high-sensitivity
C-reactive protein (hsCRP)
monocyte-derived macrophages, vascular endothelial cells,
and vascular smooth muscle cells,25 or, via antioxidant
properties of the -tocopherol structure contained in
troglitazone, reduce oxidative stress and inhibit activation
of NFB.
Although troglitazone has been withdrawn from most
markets because of liver toxicity,44 details on its effects
and mechanisms of action are of interest with respect to
the other members of the TZDs, as rosiglitazone and
pioglitazone. 
Previously we reported an increase in the ratio of large
buoyant to small dense LDL, a decrease in LDL in vitro
oxidisability, and an increase in plasma Lp(a) concentration
in obese subjects treated with troglitazone.45,46 We now
add to this the selective anti-inflammatory effects of
troglitazone in obesity: plasma levels of hsCRP, IL-6,
leptin, tPA, PAI-1 and TNF- (borderline significant)
were elevated in the obese compared with those in lean
controls, but troglitazone only reduced CRP, TNF- and
tPA. Considering the fact that low-grade inflammation is
increasingly recognised as a key process in the aetiology
and pathogenesis of insulin resistance and cardiovascular
disease, the anti-inflammatory effects of TZDs may con-
tribute to primary prevention of diabetes and result in
improved cardiovascular outcomes. Long-term prospective
studies with clinical endpoints, such as the ongoing DREAM
trial that evaluates the ability of rosiglitazone to delay
progression of type 2 diabetes in a nondiabetic population
with impaired glucose tolerance, and RECORD
(Rosiglitazone Evaluated for Cardiac Outcomes and
Regulation of Glycaemia in Diabetes), will hopefully
answer this question.
In conclusion, our data confirm the association between
increased inflammation/fibrinolysis and insulin resistance,
and show that TZDs selectively suppress plasma markers
of inflammation, independent of changes in glucose
control and, at least in part, independent of their effect
on insulin sensitivity.
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A B S T R A C T  
Aim: Congenital malformations and macrosomia in infants
of women with type 1 diabetes mellitus (DM1) still occur,
even if diabetic control is considered ‘good’ (i.e. HbA1c
below the nonpregnant upper reference value of 6.3%).
We, therefore, measured HbA1c in healthy, pregnant women
to determine whether the upper reference value for preg-
nant women should be lower than the nonpregnant value.
Methods: We investigated HbA1c, measured by high-per-
formance liquid chromatography (HPLC), in two groups
of healthy primigravid women. Group 1 (n=30; 30.0 ± 5.3
(mean ± sd) years; body mass index (BMI) before pregnancy
21.7 ± 5.3 kg/m2) had a gestational age of <18 weeks (14.5
± 2.1). Group 2 (n=32; 30.7 ± 4.9 years; BMI before preg-
nancy 23.2 ± 4.6 kg/m2) were >30 weeks (34.6 ± 2.5)
pregnant. None of the women had diabetes in the family
in the first and/or second degree.
Results: Group 1 had an HbA1c of 4.3 ± 0.3% (range 3.9-5.0)
and in group 2 the HbA1c was 4.7 ± 0.4% (range 3.6-5.9)
(p<0.001). No relation was found between HbA1c and BMI vs
birth weight, corrected for gestational age, within the groups.
Conclusions: Healthy, pregnant women had a low HbA1c,
particularly in the first trimester of pregnancy. This might
implicate that for prevention of congenital malformations
and macrosomia in pregnant DM1 women HbA1c should
be below 5% in the first trimester of pregnancy and below
6% in the third trimester.
K E Y W O R D S
Congenital malformations, HbA1c, healthy pregnant
women, macrosomia, type 1 diabetes mellitus 
I N T R O D U C T I O N
Shortly after the introduction of insulin treatment in type 1
diabetes mellitus (DM1) in 1922, maternal mortality in
pregnancy nearly decreased to the general population
level, but perinatal mortality and other complications of
diabetic pregnancies only diminished when diabetes
control improved in the course of the years.1
Greene et al. found an increase in major congenital mal-
formations of 4 to 39% in diabetic pregnancies with
HbA1c values above 12.7% (which is approximately equiva-
lent to an HbA1c value of 10%) during the first trimester.2
Recently the Diabetes and Pregnancy Group, France,
reported results from the French multicentric survey of
the outcome of pregnancy in women with pregestational
diabetes showing an increase in major congenital mal-
formations of 4.4% (twice that of the general population)
in the women with an HbA1c above 8%.3 However, Evers
et al. who performed a nationwide prospective study on
the risk of complications of pregnancy in women with
type 1 diabetes in the Netherlands found that the incidence
of all congenital malformations was already increased in
pregnancies with ‘excellent or good’ first trimester HbA1c
(<7%) to 6.3% (twice that of the general population),
although the incidence was twice as high (12.9%) as that
of those with nonoptimal HbA1c (>7%).4 So these authors
concluded that near-optimal maternal glycaemic control
(HbA1c < 7%) is apparently not good enough.
In an other report from this study in the Netherlands, the
same authors reported that despite apparently ‘good’
glycaemic control (HbA1c <7%) in type 1 diabetic pregnant
women, the incidence of macrosomia was still very high.5
The issue of optimal glycaemic control in diabetic pregnancy
is thus still not solved. It is known that HbA1c is lower in
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healthy, pregnant women, compared with the nonpregnant
state, but there is discrepancy with respect to the course
of HbA1c in nondiabetic pregnancy. Worth et al. found an
increase;6 Parentoni et al.,7 Hartland et al.,8 O’Kane et al.9
and Nielsen et al.10 found no significant change; Lind et al.,11
Hanson et al.12 and Günter et al.13 found a decrease.
We therefore measured HbA1c in healthy women in the
first and third trimester of pregnancy in order to determine
whether the upper reference value for pregnant women
should be lower than the nonpregnant value and whether
it may change during pregnancy.
M A T E R I A L S  A N D  M E T H O D S
We investigated HbA1c in two groups of healthy, primi-
gravid women who visited the Department of Obstetrics
of Leiden University Medical Centre for antenatal care.
Group 1 (n=30) was less than 18 weeks pregnant and
group 2 (n=32) more than 30 weeks. Age, body mass
index (BMI) before pregnancy and gestational age of the
women in the groups are shown in table 1. None of the
women had diabetes in the family in the first and/or second
degree. The birth weight of the 62 children, corrected for
gestational age, was normal.14
HbA1c was measured by an automated determination
with a high-performance liquid chromatography (HPLC)
analyser.15 Standard procedures were used for statistical
calculations: mean ± sd, student’s t-test for between-group
comparisons, and linear regression analysis for within-group
comparisons (HbA1c and BMI vs birth weight, corrected
for gestational age). The study was conducted according
to the Declaration of Helsinki principles. The Medical
Ethical Committee of Leiden University Medical Centre
approved the study. The participants of the study gave their
informed consent.
R E S U L T S
In group 1 the mean HbA1c (± sd) was 4.3 (± 0.3)% with a
range of 3.9 to 5.0%. Group 2 had a mean HbA1c (± sd) of
4.7 (± 0.4)% with a range of 3.6 to 5.9% (table 1 and figure 1).
The difference in HbA1c between the groups was highly
significant (p<0.001). No relation was found between
HbA1c and BMI vs birth weight, corrected for gestational
age, within the groups (group 1: HbA1c vs birth weight:
r=0.142, p=0.45 and BMI vs birth weight: r=-0.349.
p=0.07; group 2: HbA1c vs birth weight: r=0.266, p=0.14
and BMI vs birth weight: r=0.318, p=0.08).
D I S C U S S I O N
We found a low upper HbA1c range level of 5 % in the first
trimester of pregnancy, compared with the nonpregnant
upper HbA1c reference value of 6.3% in our hospital, and
a higher upper HbA1c range level of 5.9% in the third
trimester of pregnancy.
The low level of HbA1c in the first trimester of pregnancy
is caused by the low mean preprandial and postprandial
blood glucose values16 and by the increase in young eryth-
rocytes which diminishes the percentage of glycosylated
haemoglobin.17 The increase in HbA1c in the third trimester
of pregnancy is caused by the increase in the mean post-
prandial blood glucose value.16 This is in agreement with
the findings of Monnier et al. who reported that in type 2
diabetic patients the relative contribution of postprandial
glucose excursions to HbA1c is predominant in fairly
well-controlled patients, whereas the contribution of fasting
hyperglycaemia increases gradually with a worsening of
the diabetes.18
Our findings might implicate that for prevention of congen-
ital malformations and macrosomia in diabetic pregnancies,
HbA1c should be below 5.0% in the first trimester of
pregnancy and below 6.0% in the third trimester. With
respect to macrosomia, the recommendation of a low
HbA1c in the first trimester is supported by the data of
Gold et al. who showed that birth weight, corrected for
gestational age, is best correlated with the HbA1c of 0 to
12 weeks of gestational age in women with type 1 diabetes.19
So our study suggests that in order to prevent congenital
malformations and macrosomia, HbA1c in the first trimester
of diabetic pregnancy should be below 5.0%. However,
Evers et al. found self-reported severe hypoglycaemia in
41% of 264 pregnant diabetic women during the first
Radder, et al. HbA1c in nondiabetic pregnancy.
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Table 1 Data (mean ± sd) of age, body mass index (BMI) before pregnancy, gestational age and HbA1c of the groups
Age (years) BMI (kg/m2) Gestational HbA1c (%)
before pregnancy age (weeks) (range)
Group 1 (n=30) 30.0 ± 5.3 21.7 ± 5.3 14.5 ± 2.1 4.3 ± 0.3* (3.9-5.0)
Group 2 (n=32) 30.7 ± 4.9 23.2 ± 4.6 34.6 ± 2.5 4.7 ± 0.4* (3.6-5.9)
* p<0.001.
trimester and in 17% during the third trimester; these
women had a mean HbA1c of 6.4 vs 6.7% in women who
did not experience hypoglycaemia. In their study HbA1c
during the first trimester was ≤6.0% in 32% of the women
and 6.1 to 7.0% in 43%.4 For the whole pregnancy, 41 and
43% of the women had an HbA1c ≤6.0% and 6.1 to 7.0%,
respectively.
So it may be difficult to improve diabetic control during
pregnancy with the current therapeutic measures without
increasing the incidence of severe hypoglycaemia. Evers et al.
reported that women on the most sophisticated therapeutic
method in practice these days, the continuous subcutaneous
insulin infusion, had significantly more macrosomic infants
than women on treatment with multiple (≥3/day) daily
insulin injections.5 The authors argued that, in general,
the reason for this could be that women with a macro-
somic infant had a higher HbA1c and less episodes of
severe hypoglycaemia compared with women with a
nonmacrosomic infant.
Other factors could also play a role in causing complications
in diabetic pregnancy. It may be possible that wide blood
glucose fluctuations, which occur in diabetic pregnancy
as clearly shown by the continuous glucose monitoring
system,20 have a deleterious effect on their own, independent
of the mean blood glucose level, as reflected by the HbA1c.
This is in agreement with the data of Derr et al. who reported
that HbA1c is not affected by glycaemic instability.21
Unplanned pregnancies also showed more complications,
particularly congenital malformations; and pregestational
hypertension and/or diabetic nephropathy are a risk for
gestational hypertension and (pre)eclampsia.3,4
In conclusion, healthy, pregnant women had a low HbA1c,
particularly in the first trimester of pregnancy. This might
implicate that for prevention of congenital malformations
and macrosomia in pregnant, type 1 diabetic women HbA1c
should be below 5% in the first trimester of pregnancy
and below 6% in the third trimester.
However, with the current therapeutic measures it is difficult
to improve diabetic control during pregnancy to the
desired level without increasing the incidence of severe
hypoglycaemia. For the moment, the best treatment still
seems to be multiple daily insulin injections. The search
for more optimal treatment modalities of diabetic, pregnant
women should have a high priority.
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A B S T R A C T
Background: Hyper-IgD and periodic fever syndrome
(HIDS) is an hereditary autoinflammatory syndrome,
characterised by recurrent inflammatory attacks. Treatment
of HIDS is difficult, although simvastatin is beneficial
and etanercept might be effective. Studying the treatment
of a rare periodic syndrome is complicated by the varying
frequency and severity of symptoms and low prevalence.
Our aim was to develop a system of clinical observations
to evaluate effectiveness of treatment-on-demand. 
Methods: Seven fever episodes in three HIDS patients were
monitored, with and without administration of etanercept
or anakinra. We developed a clinical score, which includes
12 symptoms. In one patient, inflammatory attacks were
provoked by vaccination. 
Results and conclusions: At the onset of an attack, all
patients reported a clinical score between 20 and 25. The
score was used to quantify severity and define the end of an
attack. Reproducible monitoring of inflammatory episodes
was difficult, even in this pilot study. The effect of early
administration of etanercept was variable. In one patient,
a fever episode could be readily provoked within 12 to 24
hours by vaccination. In this patient, the IL-1ra analogue
anakinra was more successful in aborting the inflammatory
attack than etanercept. We propose that this vaccination
model will allow evaluation of treatment-on-demand in a
controlled setting.
K E Y W O R D S
Anakinra, etanercept, hyper-IgD syndrome, interleukin-1,
periodic fever, TNF, vaccination
I N T R O D U C T I O N
The hyper-IgD and periodic fever syndrome (HIDS,
MIM#260920) is an autosomal recessively inherited
autoinflammatory syndrome, caused by deficient enzyme
activity of mevalonate kinase, an enzyme in the isoprenoid
pathway. Patients present with a long history of recurrent
fever attacks, lasting three to seven days, accompanied by
chills, headache, generalised lymphadenopathy, arthralgia,
skin lesions, abdominal pain and diarrhoea. Laboratory
analysis reveals an intense acute-phase response during
fever attack; ex-vivo production of tumour necrosis factor
(TNF)- and interleukin (IL)-1 by monocytes and
macrophages is significantly higher at the time of attack.1
An attack is usually preceded by a well-recognisable pro-
dromal phase of malaise, headache and musculoskeletal
symptoms.2 Sometimes, a (trivial) stimulus can be identified
as a trigger of the attack, and most HIDS patients experience
a severe inflammatory episode after any vaccination. In
between two attacks patients are asymptomatic, although
the acute-phase response may sometimes persist. 
Until now, treatment of HIDS patients is largely supportive
and very difficult. Various standard anti-inflammatory drugs
(including colchicine, NSAIDS, steroids and thalidomide)
have failed to suppress the attacks.2,3 We have already shown
that simvastatin, an inhibitor of HMG-CoA reductase, can
be beneficial in reducing the number of days of illness
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when taken continuously.4 Reports on the response to
etanercept, an inhibitor of TNF, in HIDS have been
mixed: favourable in two children,5 uncertain in one,6 and
no effect in another child.7
Studying the effectiveness of a treatment for a rare periodic
syndrome is complicated by its variability of frequency
and severity of symptoms and its low prevalence. We have
tried to develop a system of rigorous clinical observations
to evaluate the effectiveness of treatment-on-demand.
M E T H O D S
Three female Dutch HIDS patients gave written informed
consent for participation in this study; the study was
approved by the local medical ethical committee. The
patients were not on any medication apart from that
mentioned in the case observations. They were instructed
to contact us at the first indication of a fever attack. When
that happened, the patient was admitted to hospital for
close monitoring, which included regular measurement
of body temperature and blood sampling for C-reactive
protein (CRP). 
We asked the patients to complete a daily symptom score
card, rating the absence or presence of 12 different symp-
toms and their severity on a scale from 0 to 10. These
12 symptoms were lymphadenopathy, nausea, myalgia,
arthralgia, aphthous ulcers, abdominal pain, skin lesions,
headache, sore throat, tiredness, diarrhoea and nasal
congestion. This was used to develop a clinical scoring
system to help better delineate the duration and severity
of a fever episode. By adding the scores on the individual
symptoms, a daily score could thus range from 0 to 120.
At the height of a fever episode, patients experienced
between 7 and 12 of these 12 symptoms, while the maximal
documented score ranged from 45 to 88 points. Despite
an anticipated variability in scores between patients and
between separate attacks in the same patient, all patients
reported a total score between 20 and 25 at the time of
presentation at the start of a fever attack. Thus, a score of
20 or higher was taken to represent the presence of a
fever attack, while the time point of the first score below
20 was taken as the end of the attack. 
C A S E  O B S E R V A T I O N S
Patient 1 
A 35-year-old woman had experienced characteristic febrile
attacks since the age of 3 months. At age 33, HIDS was
finally diagnosed, confirmed by mevalonate kinase mutation
analysis (table 1). During childhood, vaccinations used to
trigger febrile attacks but the administration of hepatitis
A immunoglobulin at the age of 34 years did not precipitate
any symptoms. She was closely monitored during an
attack which started with a sore throat, myalgias, fatigue,
nausea and headache (figure 1A). Her body temperature was
36.6°C at presentation. Over the next few days symptoms
increased and her body temperature quickly rose to 39.5°C,
with a maximum CRP of 102 mg/l. The symptoms of the
attack lasted four days although serum CRP concentration
was still elevated at seven days (figure 1A). 
The next time she was admitted at the start of a fever
attack, two doses of etanercept (25 mg) were administered
subcutaneously at 12 and 36 hours after presentation
(figure 1B). There was no noticeable difference in her clinical
symptoms as expressed in the clinical score, body tempera-
ture or decrease in CRP concentration between this fever
episode and the previous, untreated one (figure 1). 
Patient 2 
In this 26-year-old woman the diagnosis of HIDS was made
three years ago, after she had experienced fever episodes
since two months after birth. Childhood vaccinations
consistently precipitated febrile attacks. The diagnosis was
confirmed by mutation analysis, and an immeasurably
low mevalonate kinase enzyme activity (table 1). 
The attack during which she was monitored appeared to
be uncommonly severe with respect to the accompanying
symptoms. She did not receive treatment during this
attack which lasted seven days; she experienced massive
cervical and iliac lymphadenopathy and developed oral
and vaginal aphthous ulcers. CRP concentration rose to
a maximum of 315 mg/l after 72 hours, while her body
temperature was maximally 38.4°C (figure 2A). 
A subsequent fever episode is depicted in figure 2B. The
patient only reached our hospital some 48 hours after onset
of symptoms, and immediately after admission etanercept
Bodar, et al. Treatment evaluation in HIDS.
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Table 1 Patient characteristics
Case Age (years) Age at onset Mevalonate Mevalonate Serum IgD 
(months) kinase genotype kinase enzyme activity* (U/ml†)
1 35 3 V377I/G202R ND 2330
2 26 2 V377I/417insC <0.1% 745
3 38 1 V377I/I268T 10.7% 616
*Expressed as % of normal; †reference value IgD <100 U/ml; ND = not determined.
treatment was initiated. At that time, serum CRP concen-
tration was similar to that at 48 hours into the first attack
(263 vs 252 mg/l), as was her clinical score (74 vs 71 points)
(figure 2). After institution of treatment, the CRP concentra-
tion declined steadily, and within three days her symptoms
had disappeared (figure 2B). Thus, etanercept seemed to
shorten this attack in comparison with the previous one.
The patient maintained that the second attack was milder
and she was unconvinced of a beneficial effect.
Patient 3
Patient 3 is a 38-year-old woman with fever episodes since
birth (table 1). She was admitted to the hospital for obser-
vation of an untreated fever episode. On admission, she
complained of myalgia, arthralgia, abdominal pain and
skin lesions. Her body temperature was 36.8°C, but rose
to above 39°C within two days (figure 3A). The symptomatic
attack persisted for six days, with a concomitant rise and
fall of CRP concentration. 
Because of a planned trip to China she required several
vaccinations, and given her earlier childhood experiences
of fever attacks after vaccinations, we decided to admit
her for administration of the injections. We gave her one
vaccination for hepatitis A (a primo vaccination in her
case) and one (repeat) DTP toxin vaccination, separated
by one month. Some 24 to 48 hours after administration
of each vaccine she developed a characteristic HIDS attack
with fever, abdominal pain, myalgia and fatigue. In both
instances this was accompanied by an intense acute-phase
response (maximum CRP 166 mg/l; figures 3B and 3C).
We used this model of vaccination-precipitated HIDS
attack to test the efficacy of early institution of treatment
to abort the fever episode. In the first attack, two doses of
etanercept (25 mg, subcutaneously) were administered
72 and 86 hours after vaccination (48 and 72 hours after
onset of the first symptoms). The symptomatic attack lasted
for 5.5 days in total, with maximum CRP concentration
reaching 36 hours after the first dose of etanercept (figure 3B).
At the next vaccination one month later, we administered
anakinra, a recombinant selective  IL-1 receptor antagonist
(100 mg per dose, subcutaneously), at three time points
from 72 hours after vaccination, with an interval of 24 hours.
Body temperature normalised and symptoms disappeared
within 17 hours after the first injection, peak CRP concen-
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Figure 1 Two inflammatory attacks in patient 1
= Serum CRP concentration (mg/l) on left Y-axis; = body temper-
ature (°C) on right Y-axis; = total clinical score on left Y-axis; grey
area depicts area of clinical score below 20 points. a) untreated
inflammatory episode; b) inflammatory episode treated with etanercept
at 12 and 36 hours after onset of symptoms (denoted by arrows).
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Figure 2 Two inflammatory attacks in patient 2
= Serum CRP concentration (mg/l) on left Y-axis; = body temper-
ature (°C) on right Y-axis; = total clinical score on left Y-axis; grey
area depicts area of clinical score below 20 points. One untreated
inflammatory episode (a), and one inflammatory episode treated
with etanercept (b, denoted by arrows).
tration was reached at 12 hours after the first injection
and CRP gradually returned to baseline values (figure 3C).
Thus, anakinra aborted the attack after some three days
of symptoms, in contrast to the 5.5 and 6 days of the other
witnessed attacks. 
Antibody titres were found to be adequate after both
vaccinations (data not shown), thus demonstrating that
the administration of cytokine antagonists 72 hours after
vaccination did not have an influence on the effectiveness
of the vaccinations.
D I S C U S S I O N
In this pilot study monitoring fever attacks in HIDS, we
closely followed seven fever episodes in three patients,
with and without intervention. 
To quantify the accompanying symptoms of the inflam-
matory attack, we developed a clinical scoring system
consisting of the total scores on a visual analogue scale
on a range of 12 symptoms and signs. At the moment the
patients felt the onset of a fever attack, they documented
a total score of between 20 and 25. Since concentration of
CRP and some of the symptoms, most notably tiredness,
may persist for a longer period, the end of a HIDS attack
may be difficult to define. We found that the proposed
clinical score may help with this as well: we suggest defining
the end of the attack as the moment at which the clinical
score decreases to 20 or less.
The results of monitoring fever episodes in patients 1 and 2
demonstrate the variability of this disorder. It was our aim
to start with intervention at the earliest possible moment
and we therefore instructed patients to contact us as soon
as possible after the start of symptoms. However, even in
our small pilot study there was a difference of 36 hours
between the time of first administration of etanercept in
the two patients. The wide variation seriously impedes
the comparability of results in a larger trial set-up. Part of
the delay was caused by the fact that we admitted patients
to our clinic, which might also induce a selection bias
towards more severe attacks. However, treatment at home
would make it more difficult to objectively observe
symptoms, body temperature and CRP concentrations.
A HIDS patient who needed vaccinations allowed us to
observe the power of these vaccinations to provoke a fever
episode. In both instances, vaccination resulted in a fever
episode within 12 to 24 hours. These attacks were compa-
rable with attacks not precipitated by vaccinations. There
are some advantages to using this provocation model: it is
simple, easy to use and offers an opportunity to closely
monitor the onset of the attack from the very beginning, and
thus to standardise the time to starting treatment. Since
patients are hesitant to receive (necessary) vaccinations
because of the risk of a febrile attack, a closely monitored
setting will be helpful to ensure that they do receive them. 
With respect to the observations of effect of treatment-on-
demand in these patients: these first results appear to be
mixed, and this pilot study does not allow us to draw firm
conclusions on that point. Anakinra seems to be more
Bodar, et al. Treatment evaluation in HIDS.
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Figure 3 Inflammatory attacks in patient 3
= Serum CRP concentration (mg/l) on left Y-axis; = body temper-
ature (°C) on right Y-axis; = total clinical score on left Y-axis; grey
area depicts area of clinical score below 20 points. a) untreated
inflammatory episode; b) inflammatory episode provoked by hepatitis
A vaccination, and treated with etanercept (denoted by arrows); c)
inflammatory episode provoked by DTP vaccination, and treated
with anakinra (denoted by arrows).
successful than etanercept; this warrants further exami-
nation. HIDS is part of a group of hereditary autoinflam-
matory syndromes,8 whose common pathogenic background
seems to involve IL-1 signalling. Recently several groups
have reported treating hereditary autoinflammatory syn-
dromes successfully with the recombinant form of IL-1ra,
anakinra.9-13
It remains difficult to get solid evidence on treatment
efficacy in orphan diseases, especially when periodic and
variable in phenotype, such as HIDS. Most published
reports concern clinical observations in one or two patients.
Drug trials set up on established lines such as randomised
controlled trials will often remain underpowered because
of too few patients and too few episodes of illness.3,4 Also,
because the frequency of fever attacks in adult HIDS
patients will usually diminish to between 6 and 12 per year,
patients will be more interested in an on-demand treatment
which shortens an attack than in continuous treatment
(and continuous life-long risk of side effects), unless this
continuous treatment will abolish all further symptoms.
We suggest that the vaccination provocation model in
combination with the clinical score described in this pilot
study will offer an opportunity for more rigorous and
standardised study of on-demand treatment in HIDS.
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A B S T R A C T
Background: To study variation in Dutch hospitals in
applying diagnostic and treatment options for faecal
incontinence.
Methods: Surgeons, gastroenterologists, internists and
gynaecologists were contacted by phone or mail and
requested to complete a questionnaire. The questionnaire
asked for general information about patients with faecal
incontinence, the use and availability of diagnostic tech-
niques, the use of incontinence scores and therapeutic
options.
Results: In total 306 specialists were contacted and data
were collected from 203 specialists from 86 hospitals
(response rate 66%). The most frequently applied diagnos-
tics were sigmoidoscopy (64%), endoanal sonography (58%),
evacuation proctography (56%) and/or anorectal manometry
(51%). The choice seemed to be related to the availability of
the techniques. Sigmoidoscopies were performed signifi-
cantly more often in local hospitals (p<0.001), while in
academic medical centres significantly more endoanal
MRI examinations were conducted (p<0.05). The most
stated treatment option was physiotherapy (90%), followed
by dietary measures (83%), medication (71%) and surgery
(68%). However, in general, combinations of treatment
options were used.
Conclusions: A substantial variety exists in the diagnostic
work-up of faecal incontinence. In general, at least one
anorectal functional test and an imaging technique are the
diagnostic techniques of choice. Pelvic floor physiotherapy
is the first choice in conservative treatment.
K E Y W O R D S
Anorectal functional test, diagnostic work-up, endoanal
sonography, faecal incontinence, manometry, MRI, therapy,
survey 
I N T R O D U C T I O N
Faecal incontinence is defined as ‘the involuntary loss of
flatus, liquid or solid stool that is a social or hygienic
problem.’1 The incidence and prevalence of faecal inconti-
nence in the Netherlands are not exactly known.2 The
estimated prevalence is about 100,000 subjects in the
Netherlands. The actual prevalence may be even higher due
to underreporting as a consequence of the social stigma
of this disorder.3 The main causes of faecal incontinence
are obstetric trauma (anal sphincter and/or pudendal nerve
damage) and anorectal surgery (anal sphincter trauma).4-6
Apart from medical history and physical examination, there
are several diagnostic techniques that can be performed:
anorectal functional testing, endoscopy and imaging.7-9
Anorectal functional tests comprise anorectal manometry
(measurement of sphincter pressure in rest, during squeeze
and straining), measurement of pudendal nerve terminal
motor latency (PNTML) (to establish pudendal nerve
injury), electromyography (EMG) (conventional EMG to
identify the quality of sphincter tissue as well as to deter-
mine whether the muscle contracts or relaxes; single-fibre
EMG to identify denervation-reinnervation potentials
indicative of nerve injury), rectal capacity measurement
(to detect the threshold of the first detectable sensation,
sensation of urgency and maximum tolerable volume)
and sensory testing (to determine the sensitivity of the
anal canal and rectum).10,11
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Diagnostic work-up for faecal incontinence in
daily clinical practice in the Netherlands
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A sigmoidoscopy can be performed to exclude organic
disease, such as a benign or malignant obstructing lesion or
inflammation.10 With imaging techniques, such as endoanal
sonography and magnetic resonance imaging (MRI), both
internal and external anal sphincter abnormalities will be
assessed.7 Evacuation proctography (defaecography) involves
imaging of the rectum and observation of the process,
rate, and completeness of rectal evacuation.10
At present there is no consensus on the best diagnostic
techniques for patients with faecal incontinence in the
Netherlands. As a consequence of the increase in number
and availability of diagnostic modalities, variation in
diagnostics exists and an unambiguous strategy is lacking.10
To assess if and to what extent variation exists in diagnostic
work-up and treatment of patients with faecal incontinence
in daily clinical practice in the Netherlands, we developed
a survey. We restricted ourselves to an inventory of diag-
nostic modalities and treatment in secondary and tertiary
centres. 
M A T E R I A L S  A N D  M E T H O D S
From October 2002 to April 2004 surgeons, gastroenterol-
ogists, internists and gynaecologists from all Dutch hospitals
were informed about the survey by phone. If approach by
phone turned out to be impossible, information was sent
out by (digital) mail. For every hospital a questionnaire
was sent per discipline to the most experienced specialist
in the field of faecal incontinence. 
The questionnaire comprised five sections. In the first,
physicians were asked for general information about
patients with faecal incontinence, such as how often these
patients were referred to the respondent, and the age, and
gender of the referred patients. In the second section
information was requested about the selection of diagnostic
tests which were used as routine work-up in patients with
faecal incontinence. Options were anorectal functional tests,
endoscopy and imaging techniques (table 1). In addition
to the options for routine diagnostic techniques, in the
third part questions were asked about the availability of
these techniques to gain insight into where the techniques
were performed. The respondent had to indicate whether
the diagnostic test in question could be performed in the
respondent’s own hospital or if referral was needed. The
fourth section was about the use of an incontinence score
to determine the severity of incontinence. Respondents
could choose between the Parks, Vaizey, Wexner, Pescatori,
or Millar scores, and/or the American Medical System
score.12 If an incontinence score was used, the respondent
was asked whether the score influenced the choice of
diagnostic and therapeutic options. The final section
contained questions on the therapeutic options used
(conservative therapy (dietary measures, medication, pelvic
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Table 1 Options for diagnostic techniques together with the availability of diagnostic equipment and referral of patients
with faecal incontinence
Options for Availability of Referral
diagnostics* diagnostics n (%)
Diagnostic techniques n (%) n (%)
Endoscopy
Sigmoidoscopy 120 (64) 166 (89) 2 (1)
Anorectal functional tests
Anorectal manometry 96 (51) 71 (38) 72 (39)
Rectal capacity measurement 42 (22) 44 (24) 48 (26)
PNTML 37 (20) 47 (25) 43 (23)
Anal sensibility measurement 32 (17) 33 (18) 47 (25)
Rectal sensibility measurement 31 (17) 23 (12) 46 (25)
Conventional electromyography 26 (14) 57 (31) 26 (14)
Fine needle electromyography 6 (3) 24 (13) 22 (12)
Imaging techniques
Endoanal sonography 108 (58) 86 (46) 60 (32)
Evacuation proctography 104 (56) 136 (73) 31 (17)
Endoanal MRI 25 (13) 28 (15) 31 (17)
Phased-array MRI 25 (13) 56 (30) 10 (5)
MR defaecography 3 (2) 11 (6) 13 (7)
*The chosen diagnostic is the routine diagnostic work-up in patients with faecal incontinence. The routine diagnostic work-up could be performed in
the respondent’s own hospital or in a referring centre. PNTML = pudendal nerve terminal motor latency; MRI = magnetic resonance imaging.
floor physiotherapy), surgery or another kind of therapy).
All nonrespondents received one more reminder by phone
and if necessary, a new questionnaire was sent out. If
there was no response after three questionnaires had
been sent out, a final nonresponse was determined.
(Details of the questionnaire can be obtained from the
corresponding author.)
Analyses were performed with descriptive statistics.
Differences between groups were calculated with 2 test.
The results were statistically analysed with SPSS 11.5. for
Windows (SPSS Inc. Standard Version). We analysed the
response per specialist instead of per hospital. 
R E S U L T S
Response
In total 306 physicians were contacted (91 surgeons, 74
gastroenterologists, 24 internists and 117 gynaecologists)
from the 100 Dutch hospitals (we did not take into account
categorical hospitals such as cancer institutes and out-
patient clinics). The response rate was 66% (n=203) from
86 hospitals and one private clinic. Sixteen percent (n=33
questionnaires) of the response rate originated from
academic medical centres. There were differences in
response rate per medical specialist: the response rate of
surgeons and gastroenterologists was higher (76 and 72%
respectively) than that of internists and gynaecologists
(58 and 57% respectively). Seventeen (29%) responding
gynaecologists referred their patients almost directly to
another medical specialist or hospital. For the majority of
physicians (75%) patients with faecal incontinence were
sometimes referred, while only 12% indicated having
these patients referred regularly and 3% often. 
Sixteen questionnaires (8%) had to be excluded from
analysis since the respondent reported no referral of
patients with faecal incontinence or referred these patients
immediately to another specialist. Consequently, there
were 187 questionnaires remaining for analysis, from
80 different hospitals and of one private clinic. 
The majority of physicians (92%) indicated that they
treated their patients with faecal incontinence on an
interdisciplinary and/or multidisciplinary basis. 
Patients
Physicians indicated that on average 87% of the patients
with faecal incontinence were female. On average almost
half of these patients (47%) were more than 65 years of
age. Age as well as gender was not significantly influenced
by the numbers of patients referred to the physician. 
Diagnostic techniques
The range of routine diagnostic techniques applied in
patients with faecal incontinence varied from none to 11
examinations. On average 3.5 examinations were performed
as the routine diagnostic work-up. In table 1 the results of
differences in options of diagnostic testing are shown. The
majority of the respondents (64%) indicated the routine
use of sigmoidoscopy. The most frequently applied imaging
techniques were endoanal sonography (58%) and evacua-
tion proctography (56%). Of all anorectal functional tests,
anorectal manometry (51%) was most often used. The use
of these techniques seems to be linked to the availability of
the diagnostic techniques. The other diagnostic techniques
were not performed on a regular basis. 
Sigmoidoscopy and evacuation proctography were available
for most of the respondents. The highest percentages of
referral were for endoanal sonography and anorectal
manometry (32 and 39% respectively). The most commonly
used combinations of diagnostic techniques were endoanal
sonography with anorectal manometry (41%), and sig-
moidoscopy with evacuation proctography (41%). Twelve
percent of all respondents reported that they did not perform
any kind of additional testing; 38% mentioned not per-
forming any anorectal functional tests and 3% reported
that they did not make use of any kind of imaging technique.
When comparing the routinely performed diagnostics in
academic medical centres with those performed in local
hospitals, physicians in local hospitals reported significantly
more use of sigmoidoscopy (p<0.001), while physicians
in academic medical centres reported significantly more
use of endoanal MRI examinations (p<0.05) (table 2).
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Table 2 Significant differences between academic medical
centres and local hospitals
Sigmoid- Endoanal Incontinence 
0scopy MRI score
University hospital 15% 29% 60%
p<0.001 p<0.05 p=0.001
Local hospital 73% 11% 28%
Incontinence score
Thirty-one percent of the respondents used an incontinence
score; 13.5% indicated that they always used a score and
17.5% sometimes. A score was significantly more in use
in academic medical centres compared with local hospitals
(p=0.001) (table 2). The most applied incontinence score
was the Parks score (44%), followed by the more recently
introduced Vaizey score (28%). The selection of diagnostic
tests and therapeutic treatment options were influenced
by an incontinence score in 6%.
Therapeutic treatment options
The most reported treatment option by the respondents
was pelvic floor physiotherapy (90%), followed by dietary
measures (83%), medication (71%) and surgery (68%). A
combination of treatment options was most frequently
reported. Fifty-four percent of the respondents indicated
that they applied dietary measures, medication, pelvic
floor physiotherapy as well as surgery as treatment options.
In 7% (academic medical centres) vs 26% (local hospitals)
surgery was not considered a treatment option as patients
only received conservative treatment. Other therapies,
such as sacral neuromodulation and anorectal or oral
water enemas, were part of potential treatment options in
7% of the respondents. 
D I S C U S S I O N
In the Netherlands the most performed diagnostics in
patients with faecal incontinence are sigmoidoscopy,
endoanal sonography, evacuation proctography and
anorectal manometry. Since sigmoidoscopy is performed
to exclude local pathology such as tumours, and evacuation
proctography is not a diagnostic technique specifically for
faecal incontinence,7 it can be concluded that most applied
diagnostic tests in patients with faecal incontinence in
secondary and tertiary centres are anorectal manometry
(anorectal functional test) and endoanal sonography
(imaging technique). 
Significantly more sigmoidoscopies were performed in local
hospitals (p<0.001), while endoanal MRI examinations
were significantly more frequent in academic medical
centres (p<0.05). It is possible that availability does play a
role, as well as the referral pattern. Almost every physician
in a local hospital performs a sigmoidoscopy to exclude
malignancy or proctitis, for example, while in general
patients are referred to an academic medical centre if
comprehensive anorectal functional testing and/or endoanal
MRI is needed. There was a considerable variation in the
use of the other diagnostic modalities. 
Anorectal functional tests
Anorectal manometry appeared to be the most commonly
applied anorectal functional test; it was relatively widely
available and had the highest percentage of referral.
PNTML, rectal capacity measurement, and anal and rectal
sensory testing were part of routine diagnostic testing to a
lesser extent. Nevertheless, approximately 25% of the
respondents referred their patients for these tests. It seems
that these functional tests are included in the work-up
when more extensive diagnostic is mandatory. 
Conventional electromyography was reported to be part of
the available diagnostic techniques by 31% of all respondents,
but only 14% performed it as a routine procedure. Fine
needle electromyography was not regarded as routine.
These tests are not considered to have any substantial
value and to be outdated. The performance of EMG for
the detection of an external anal sphincter defect has
been replaced by the availability of other techniques, such
as endosonography or MRI.10,13 For establishing pudendal
nerve injury, PNTML measurement will be performed
when considered appropriate.7 The technique has been
suggested for distinguishing between muscle weakness
caused by pudendal nerve injury and muscle weakness
caused by muscle injury in patients with faecal incontinence,
but has a poor correlation with clinical symptoms and
histological findings. Therefore, the clinical usefulness is
controversial.10
Imaging techniques
Endoanal and phased-array MRI are part of the routine
diagnostic work-up for more than 10% of respondents.
Endoanal sonography and endoanal MRI are comparable
techniques for evaluating external anal sphincter abnor-
malities. For evaluation of the internal anal sphincter
complex, there is no consensus about the most accurate
technique.8,14,15 However, the sensitivity and specificity for
identifying external anal sphincter atrophy with MRI is
higher than for endoanal sonography.8
MR defaecography is hardly available. Besides, the accuracy
and reproducibility of conventional defaecography is not
(yet) established and the technique is still in development.14
Incontinence score
Several incontinence scores have been developed.7,8,12
Nevertheless, it appears that these scores are rarely used
in daily practice. This is probably because the registration
of scoring is often a complex matter and the consequences
of use, other than for scientific research, have not been
clearly pointed out. This study showed that scoring systems
according to Parks and Vaizey are the most applied scores
in the Netherlands for patients with faecal incontinence.
Possible explanations are that the score according to Parks
is the most uncomplicated one and the score according to
Vaizey is the most complete scoring system.12
Treatment options
A combination of treatments was predominantly reported,
comprising various conservative treatment options (pelvic
floor physiotherapy, dietary measures, medication), if
necessary complemented with surgery. Of all therapeutic
options, pelvic floor physiotherapy was the most widely
applied (90%). According to Kamm pelvic floor physio-
therapy and surgery are the two most utilised treatment
options if dietary measures and/or medication fail.16
However, in this study the respondents reported that they
more often used pelvic floor physiotherapy as initial therapy
than other conservative measures. Nevertheless, we must
consider that previous conservative treatment may have
been prescribed elsewhere by others. 
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Limitations
Potential limitations of this study should be taken into
account. One limitation was that the majority of the
respondents reported a relatively infrequent referral of
patients with faecal incontinence, which was defined as a
range from 1 to 24 patients a year. Because of the wide
range, it is possible that differences exist in selected
diagnostic and therapeutic options between physicians
with one to five referrals a year compared with those with
20 to 24 referrals on a yearly basis. 
In some of the participating hospitals this questionnaire
was completed by several medical specialities while in
others it was completed by only one speciality. Since this
questionnaire was completed for the greater part by different
medical specialities divergently, we assume it is justified
considering that all hospitals have the same weighting. 
This study shows that substantial variety exists in the
diagnostic work-up for faecal incontinence. In general, at
least one anorectal functional test and an imaging technique
are the diagnostic techniques of choice. Besides, there are
differences in work-up between local hospitals and academic
medical centres, partly related to the availability of equip-
ment. In the literature, guidelines for the evaluation of
faecal incontinence are described.10,17-19 In summary they all
recommend, next to a detailed clinical assessment, appro-
priate physiological and imaging tests of the anorectum.
These three sources of information are complementary.
The anorectal physiology testing of choise in the presented
guidelines were anorectal manometry and endoanal
sonography, conform the results of our study. Furthermore,
between guidelines there was variation concerning the
remaining diagnostic modalities. 
To reduce variability we encourage developing guidelines
for the diagnostic work-up of faecal incontinence in the
Netherlands. We recommend that the scope of the guide-
lines is aimed at simplification of the diagnostic path in
patients with faecal incontinence, based on scientific evi-
dence. We want to emphasise the importance of evidence-
based guidelines to reduce inadequate use as well as both
overuse and underuse. As a consequence, an efficient
diagnostic work-up in patients with faecal incontinence
can be developed.
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A B S T R A C T
In systemic vasculitis, cytoplasmic staining in ethanol-fixed
neutrophilic granulocytes, i.e. cytoplasmic antineutrophilic
cytoplasmic antibody (c-ANCA), is generally considered a
highly significant serological marker. When a patient
presents with upper airway or renal symptomatology and
seropositivity to c-ANCA, a Wegener’s granulomatosis is
usually easily diagnosed by performing a biopsy of the
diseased organ. However, not every ANCA-positive patient
with pulmonary inflammation is suffering from Wegener’s
disease. In some cases of upper airway or pulmonary
symptomatology, the a priori chance of having Wegener’s
disease is low despite a positive ANCA. A coincidental
positivity of ANCA may then lead to clinicians jumping to
conclusions. We present a 40-year-old man who was falsely
suspected of having Wegener’s disease because of upper
airway symptomatology and c-ANCA positivity. Specificity
analysis revealed that he was negative to antibodies for
proteinase-3, but positive to myeloperoxidase. The potential
serological pitfall of the supposedly specific c-ANCA is
discussed.
K E Y W O R D S
ANCA, HIV, pitfall, screening
I N T R O D U C T I O N
Wegener’s granulomatosis is a necrotising granulomatous
vasculitis involving predominantly the upper and lower
respiratory tract and kidneys. Other organs may be affected
to a variable extent by this small-vessel vasculitis. Some
authors have suggested that sensitivity and specificity of
antineutrophilic cytoplasmic antibodies (ANCA) are ade-
quate to merit inclusion of ANCA in classification systems
of systemic vasculitis. Many clinicians therefore even use
ANCA in a similar way to antinuclear antibodies (ANA)
early in the diagnostic phase for screening purposes.1
Positivity of these ANCA may be misleading if clinicians
have requested the tests incorrectly in these screening
diagnostic situations. They may even become a diagnostic
pitfall.2,3 Such patients enter specialist care via different
disciplines, i.e. general internists, pulmonologists,
nephrologists, ear, nose and throat (ENT) specialists or
rheumatologists, depending on the predominant clinical
sign or symptom. In addition to pulmonary and renal
involvement, antineutrophilic cytoplasmatic antibodies
with a typical cytoplasmic staining pattern on ethanol-fixed
neutrophilic granulocytes (c-ANCA) with a proteinase-3
(PR3) specificity has proven to be a valuable serological
hallmark in the differential diagnosis of Wegener’s disease.1
The majority of papers focus on ANCA being highly
specific, whereas only a minority deal with ANCA positivity
as coincidental, i.e. ‘false-positive’, for example in screening
settings. In the presented case we demonstrate the potential
of ANCA as a diagnostic pitfall in the screening setting of
clinical practice.
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C A S E  R E P O R T
ANCA seropositivity in HIV: a serological pitfall
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C A S E  R E P O R T
A 40-year-old male was admitted to the general internal
medicine department for analysis of malaise with fever.
He had experienced progressive fatigue during the past
six months. There was no weight loss or loss of appetite.
He did mention having a paronychium with a tendency
toward delayed healing for a three-month period. Surgical
debridement with amoxicillin/clavulanic acid 500/125 mg
four times a day was prescribed, but the problem with
wound healing persisted. He also mentioned having a non-
productive cough for about a year, with slight progression
over the last two months. At rest he experienced slight
dyspnoea, and he had nasal symptoms with haemorrhagic
crustae. During admission to the ward he had a fever of up
to 39°C and chills despite the aforementioned antibiotic
regimen. Physical examination revealed a feverish man
with red cheeks and normal tension without tachypnoea:
respiration frequency was 12/min. On auscultation of the
lungs, dry inspiratory crackles were heard in the basal fields.
His left digit finger was slightly inflamed but appeared to
be healing. Further examination was unremarkable. X-rays
of the thorax revealed some interstitial abnormalities in
the lower left and right pulmonary lobes, without further
abnormalities (figure 1). Laboratory investigations were as
follows: ESR >90 mm/h, haemoglobin 7.9 mM (normal
>8.2 mM), leucocytes 2.2 x 109/l (normal 4.0-10.0 x 109/l),
platelets 143 x 109/l (normal 150-300 x 109/l), with only
0.5 x 109/l lymphocytes. For further data see table 1. 
In order to rule out the possibility of an autoimmune dis-
order, blood was drawn for ANA and ANCA. The latter
was analysed via an indirect immunofluorescent (IIF) test
with serum on activated, ethanol-fixed human granulocytes
(prepared within our laboratory). The cytological appearance
(figure 2) shows the staining pattern, originally interpreted
as typical c-ANCA. To determine the specificity of the
antibody, a dot blot (BMD) was incubated with the patient’s
serum. The expected PR3 specificity could not, however, be
confirmed; instead the analysis resulted in an myeloper-
oxidase (MPO)-positive c-ANCA pattern. The discrepancy
between the cytological pattern and specificity led us to
offer the sample to two other laboratories for reanalysis.
The results are given in table 2.
Jansen, et al. ANCA seropositivity in HIV.
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Figure 1 X-ray of lungs: interstitial alveolitis in
immunodeficient patient
Table 1 Biochemical findings in the presented patient
Hb 7.9 (8.0-10.6) mmol/l Ht 0,39 (0.40-0.52) l/l
ESR >90 (<15) mm/h CRP 10 (<10) mg/l
Leucocytes 2.2 (4.0-11.0) 109/l Neutrophils 1.3 (2.0-7.5) 109/l
Lymphocytes 0.5 (0.8-3.2) 109/l Platelets 143 (150-400) 109/l
Sodium 137 (136-146) mmol/l Potassium 3.5 (3.5-5.0) mmol/l
Creatinine 71 (<105) mol/l Urea 2.5 (2.8-7.5) mmol/l
LDH 540 (<475) U/l ASAT 30 (<45) U/l
ALAT 37 (<45) U/l AP 90 (<120) U/l
Normal values are given between brackets. Hb = haemoglobin; ESR = erythrocyte sedimentation rate; LDH = lactate dehydrogenase; ALAT = alanine
aminotranspeptidase; Ht = haematocrit; CRP = C-reactive protein; ASAT = aspartate aminotranspeptidase; AP = alkaline phosphatase. 
Figure 2 Cytoplasmic ANCA
Nasal biopsies were performed by the ENT specialist and
the rheumatologist was consulted for confirmation of
suspected Wegener’s disease and for subsequent treatment
options. On consultation no signs or symptoms were seen
of arthritis, arthralgia, uveitis or neuropathy. The urine
remained unremarkable. Additionally, history was taken
focussed on the infectious diathesis and the patient con-
fessed to having had various sexual contacts all over
Europe without protection. There was a leucocytopenia,
confirmed by a hand differentiation with specifically a
CD4-positive lymphocytopenia: CD4-positive lymphocytes
18 x 106/l (normal 460-1450 x 106/l) and CD8-positive
lymphocytes 123 x 106/l (normal 210-950 x 106/l) with a
CD4/CD8 ratio of 0.15 (normal >1.0); see table 3 for a
differential diagnosis. A HIV infection was suspected and,
after consent had been obtained from the patient, a rapid
HIV test was requested. At the same time the following
results came back: bacteriological analysis of the broncho-
alveolar lavage revealed Pneumocystic carinii and the rapid
HIV test was positive; further analysis revealed a high viral
load. The patient was concluded to have AIDS category C3
with Pneumocystic carinii pneumonitis and a coincidental
MPO-positive ANCA without clear signs of vasculitis. He
was treated with cotrimoxazole-sulfamethoxazole and
subsequently with highly active antiretroviral therapy. The
positive ANCA gradually resolved.
D I S C U S S I O N
Tests for circulating ANCA with specificity for MPO or PR3
are of considerable value in the diagnosis of the spectrum
of vasculitides including Wegener’s granulomatosis,
microscopic polyangiitis, the Churg-Strauss syndrome,
idiopathic necrotising and crescentic glomerulonephritis,
and related overlapping forms of vasculitis.1 Patients
meeting two or more of the four American College of
Rheumatology criteria can be classified as having Wegener’s
granulomatosis with a sensitivity of 88% and a specificity
of 92%. The triggers that induce ANCA positivity, however,
are largely unknown. Furthermore, in some cases ANCA
positivity has been associated with medication: hydralazine,4,5
minocycline6,7 and propylthiouracil.8,9 Cocaine abuse has
sporadically been associated with ANCA.3,10,11 Positivity of
ANCA has also been found secondary to HIV infection.
HIV infection may evoke ANCA in 20 to 83% of cases,2,12-15
probably due to polyclonal activation of B cells,12,15 but not
associated with hypergammaglobulinaemia.2 Savige et al.
found 44 patients (42%) with ANCA on immunofluores-
cence testing out of 105 HIV-infected patients, including
26 with MPO specificity,13 whereas Cornely et al. found
40 ANCA-positive patients (20%) out of 199 HIV-infected
patients, 67 of whom revealed an atypical pattern and 33%
a p-ANCA pattern.14 Cornely et al. found MPO positivity
in only one out of 199 HIV patients (0.5%),14 whereas
Koderich et al. found a faint c-ANCA positivity in 24 out
of 29 HIV-infected patients (83%).15 The last-mentioned
24 HIV-infected patients had homogeneous cytoplasmic
ANCA probably representing nonspecific Fc-receptor
binding of immunoglobulin G since this staining pattern
was found particularly in 15 hyper-gammaglobulinaemic
patients in this group. None of these HIV-infected patients
showed p-ANCA, but five patients were repeatedly borderline
positive in ANCA-enzyme-linked immunosorbent assays
(ELISA) whereas three patients had positive MPO-ELISAs.
Clinicians should be aware of the possibility of a false-
positive ANCA, particularly in view of the current HIV
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Table 2 Serological findings from our laboratory and
two reference laboratories
Our lab Lab 1 Lab 2
ELISA technique Direct Capture Direct
ANCA pattern c-ANCA Atypical or c-ANCA
c-ANCA-like
Titre 1:80 1:320 1:80
Specificity MPO Non MPO
Interpretation MPO Atypical MPO
Lab 1 = serology laboratory university hospital 1; Lab 2 = serology
laboratory university hospital 2.
Table 3 Differential diagnosis of CD4 lymphocytopenia17
Infection
Retrovirus: HIV-1, HIV-2, HTLV-1
Herpesvirus: varicella zoster virus, human herpes virus type 6,
cytomegalovirus
Adenovirus/parvovirus/papillomavirus/rubeolavirus
Hepatitis B virus
Protozoa: leishmania
Ricketsia
Fungals: histoplasma, cryptococcus, coccidiomycosis
Bacterial: tuberculosis, brucella
Autoimmune disease
Lupus, primary Sjögren’s syndrome,18 etc.
Malnutrition
Medication
Corticosteroids
Lymphoreticular malignancy
Lymphoproliferation
Thymoma
Lymphangiectasia
Congenital disorders
Hypogammaglobulinaemia
Di George syndrome
Ageing
Pregnancy
epidemiology. This warning may become more and more
relevant for clinicians with the increasing application of
protocol screening and new ANCA test systems in systemic
vasculitis.15
Selective reading by young clinicians, as well as premature
closure of the diagnostic process, and publication bias on
the specificity of ANCA may lead to erroneous interpreta-
tion particularly with a confounding clinical copresentation
of deformation of the nasal septum,3 or pulmonary symp-
tomatology as in the presented case. Our patient presented
with nasal formation of crustae and an unproductive cough
for a period of about a year. Physical examination revealed
signs of inflammation with a subfever of up to 39.0°C
with certain Wegener-compatible interstitial abnormalities
on chest X-rays, which turned out to be due to Pneumocystis
carinii. At first leucocytopenia and thrombocytopenia were
both overlooked and the clinician’s attention was drawn
to abnormalities in serology, as our laboratory rapidly
delivered a positive c-ANCA.
The diagnostic accuracy of ANCA was evaluated in a large
multicentre European collaborative study including 169
newly diagnosed and 189 historic patients with idiopathic
systemic vasculitis or rapid glomerulonephritis, and 184
disease controls and 740 healthy controls.16 Both indirect
immunofluorescence testing and anti-PR3 and anti-MPO
ELISA were evaluated. The sensitivity of c-ANCA for
Wegener’s disease was 64% using the indirect immuno-
fluorescence test, which could be improved to up to 73%
by using a combination, either c-ANCA plus anti-PR3 or
p-ANCA plus anti-MPO. In these validation populations
no HIV-infected patients were included as far as we know.
Even though clear symptoms of Wegener’s disease are
absent, there seems to be a real risk that clinicians may
jump to conclusions in cases with a clinical suggestion of
Wegener’s granulomatosis. One may be asked for confir-
mation of the diagnosis and subsequent treatment. This
may result in a potentially dangerous situation as cytotoxic
therapy for Wegener’s disease may well be fatal in AIDS.
A similar situation has been described by Rowshani et al.,
who reported a case with cocaine abuse and a subsequent
erroneous interpretation of the clinical status with subse-
quent erroneous cytotoxic treatment.3
Specificity analysis of the antineutrophilic antibodies in the
presented case, however, revealed MPO specificity. Others
have reported on MPO-positive Wegener’s disease; then
staining specificity is, however, not cytoplasmic but perin-
uclear (as is expected with MPO specificity). Sera were
sent for a second opinion to two university laboratories.
The discrepancy between the results from these two 
laboratories was striking but this incongruence partly
results from the different interpretation strategies and
partly from a different laboratory technique: a direct ELISA
has a different specificity than a capture ELISA. Capture
ELISA is superior to direct ELISA with respect to specificity
as it captures the MPO which therefore does not cross-react.
The typical ANCA staining pattern shows accentuation of
fluorescence intensity in the area within the nuclear lobes.
Every positive IIF should be followed by an antigen-specific
test for PR3 and MPO. PR3-ANCA is highly specific for
idiopathic small-vessel vasculitis, whereas MPO-ANCA
have been reported in various conditions not associated
with vasculitis, i.e. specific drugs, infections and some
connective tissue diseases.
The presented patient was sexually promiscuous and on
presentation had a leucocytopenia with specifically a lym-
phocytopenia. Further analysis even revealed a specific
CD4-positive lymphocytopenia. This leads to a differential
diagnosis focussed on sexually transmittable diseases
including HIV (table 3).17,18 Indeed HIV serology was
positive. The load of HIV replicates was determined and
found to be sky-high. ANCA disappeared spontaneously
during specific anti-HIV therapy. The patient did not
develop other rheumatological problems i.e. no clinically
apparent vasculitis, arthritis or arthralgia. Monteagudo et al.
found a systemic necrotising vasculitis in only 1% of 106
cases with drug-induced AIDS.19 In the presented c-ANCA
positive, MPO-positive patient a vasculitis was not, how-
ever, found.
We conclude that in view of the increasing screening
application of ANCA, one should be aware of false-positive
results in all clinical presentations, in cases without specific
a priori risk, and only vague upper airway/pulmonary
symptomatology. History taking in ANCA-positive patients
should include data on sexual promiscuity and other risk
factors of HIV infection. A careful work-up is mandatory
in patients in whom Wegener’s granulomatosis is sus-
pected, even when c-ANCA is suggested or even found
positive. This report may serve again as a warning for the
pitfall of positive ANCA in HIV-infected patients.
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‘Biesbosch eilandenkaart VIII’
Miek Coppens
A B O U T  T H E  C O V E R
This month’s cover is a linocut made by Miek Coppens
entitled ‘Biesbosch Eilandenkaart VIII’. 
Miek Coppens (1944) attended the Academy of Arts in
Tilburg. After graduation she studied in Hungary at the
International Art Colony. From 1992 she exhibited her
work in several group exhibitions in the Netherlands. In
1996 she made her breakthrough internationally and
exposed her work from Japan to Russia and in many
countries in between. Her work has been appreciated, 
which has resulted in her receiving many awards such as
the Certificate of Merit, 3rd International Female Artists’
Art Annual in Stockholm and the Certificate of Merit
Mask II in Venice. 
An original print of this linocut (limited edition of four)
is available at a price of € 250 and can be ordered from
Galerie Unita, Rijkkstraatweg 109, 6573 CK Beek-Ubbergen,
the Netherlands or by e-mail: galerie-unita@planet.nl or
www.galerie-unita.com.
A B S T R A C T
We report a female patient who repeatedly developed
pancreatitis after trimethoprim-sulfamethoxazole
(TMP/SMX) use. During childhood she had undergone
an ureterosigmoidostomy after which she had been on
TMP/SMX 480 mg daily as prophylaxis for pyelonephritis
for many years. The patient presented with abdominal
pain caused by acute pancreatitis. No other cause, except
for TMP/SMX use, could be identified. A causal relation-
ship was confirmed by relapse of the pancreatitis after
rechallenge. Our case is unique in demonstrating that acute
pancreatitis related to the use of TMP/SMX may occur even
after long-term treatment. We advise that the medication
is discontinued immediately if a causal relationship with
pancreatitis is suspected.
K E Y W O R D S
Co-trimoxazole, drugs, pancreatitis, rechallange,
trimethoprim-sulfamathoxazole 
I N T R O D U C T I O N
Drug-related acute pancreatitis remains an uncommon
clinical entity. Some cases of pancreatitis associated with
the use of trimethoprim-sulfamethoxazole (TMP/SMX)
have been reported previously (table 1).1-6 In all of these,
clinical symptoms occurred within days to weeks after the
onset of treatment. We report a case that is unique in that
acute pancreatitis occurred after many years of treatment
with TMP/SMX. Furthermore, a causal relation was demon-
strated by recurrent symptoms following drug rechallenge.
© 2005 Van Zuiden Communications B.V. All rights reserved.
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C A S E  R E P O R T
Recurrent pancreatitis after trimethoprim-
sulfamethoxazole rechallenge
M.W.J. Versleijen1, A.H.J. Naber1*, N.P. Riksen1, G.J. Wanten1, F.M.J. Debruyne2
Departments of 1Gastroenterology and Hepatology, and 2Urology, Radboud University Nijmegen
Medical Centre, PO Box 9101, 6500 HB Nijmegen, the Netherlands, tel.: +31 (0)24-361 47 60, 
fax: +31 (0)24-355 79 57, e-mail: T.Naber@mdl.umcn.nl, *corresponding author
Table 1 Documented case reports of TMP/SMX-induced acute pancreatitis
Reference Indication for Daily TMP/SMX Onset (days) of Onset of pancreatitis 
TMP/SMX use treatment (mg) pancreatitis after after rechallenge
start of TMP/SMX
1 Occipital abscess with 960/4800 7 3
Nocardia asteroids
2 Urinary tract infection 320/1600 Only hepatitis after ‘Several days’ (hepatitis 
first exposure and pancreatitis)
3 Ear infection 320/1600 5 No rechallenge
4 Occipital abscess with 1600/8000 42 No rechallenge
Nocardia
5 Pneumocystis carinii 1280/6400 10 No rechallenge
pneumonia (HIV pos.)
6 Pneumocystis carinii 900 6 No rechallenge
pneumonia (HIV pos.)
C A S E  R E P O R T
A 53-year-old woman presented with epigastric pain, radiating
to the back. Her history revealed an ureterosigmoidostomy
performed at the age of four years, according to the Coffey
technique, because of extrophia vesicae. Next, she developed
numerous episodes of pyelonephritis for which treatment
with prophylactic antibiotics in the form of TMP/SMX
(480 mg daily) had been initiated more than twenty years
before. In addition, in later years hyperthyroidism and
ulcerative colitis were diagnosed. Also, she developed a
prolapsed uterus for which vaginal surgery was performed.
At the time of presentation, she was not taking any drugs
other than TMP/SMX. 
The patient complained of continuous, left-sided epigastric
pain, radiating to the back, which had been present for
four days. The pain reminded her of an episode, one year
earlier, during which she suffered from epigastric pain
and nausea that increased after eating. At that time, the
serum amylase had been normal.
During the current episode of epigastric pain she did not
report nausea, vomiting or weight loss, and she had a
good appetite. There was no alcohol or nicotine abuse.
Physical examination was not remarkable, except for a mild
tenderness in the epigastric region and some percussion
pain in the left kidney region. There was no hepato-
splenomegaly. Laboratory evaluation revealed an increase
in the serum amylase, a metabolic acidosis and symptoms
of inflammation (table 2). Other routine laboratory values
were normal. Plain abdominal X-ray only showed a colon
filled with faeces. Abdominal ultrasonography was not
remarkable except for a uterus myomatosis. The pancreas
could not be visualised due to air-filled intestines.
Gastroduodenoscopy showed no abnormalities, especially
not in the peripapillary region. Therefore, the diagnosis
of acute pancreatitis was made. The patient was treated
conservatively (nil by mouth) and received paracetamol
1 g/6 h, as a suppository, for pain relief. Bicarbonate was
provided to correct the metabolic acidosis, which was
ascribed to bicarbonate loss through the ureterosigmoidos-
tomy. TMP/SMX was continued. The clinical condition
improved within three days and the CRP and serum amylase
level decreased to 124 mg/l and 151 U/l respectively. On
the fourth day the patient was discharged. A magnetic
resonance cholangiopancreatography (MRCP), which was
performed after discharge, showed no abnormalities,
especially no bile stones. The pain gradually decreased.
Since pancreatitis can be caused by TMP/SMX, this anti-
biotic was replaced by ciprofloxacin. Eventually, the
abdominal symptoms disappeared completely. 
After some weeks of treatment with ciprofloxacin, the
patient developed headaches, diarrhoea, fever and swollen
axillary glands. Ciprofloxacin was stopped and TMP/SMX
(480 mg twice a day) restarted. The serum amylase level
was normal (156 U/l) on the day treatment was restarted
(day 1, episode 3, figure 1). Within four days the epigastric
pain recurred and the amylase level again increased to
1161 U/l (day 5, episode 3, figure 1). The diagnosis of a
relapse of acute pancreatitis was made. TMP/SMX was now
replaced by amoxicillin-clavulanic acid. After two days,
the serum amylase decreased to 245 U/l and the epigastric
pain disappeared. Because the patient developed abdominal
discomfort while taking amoxicillin-clavulanic acid,
trimethoprim was prescribed. In the following months
she did not take any sulphonamides and did not have any
further episodes of epigastric pain.
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Table 2 Laboratory values at admission (day one,
episode two)
CRP 141 mg/l 
Amylase 782 (<220) U/l
pH 7.31 
pO2 11.6 kPa
pCO2 5.1 kPa
Bicarbonate 18.9 mmol/l
Base excess -6.8 mmol/l 
Calcium 2.44 (2.20-2.60) mmol/l
Triglycerides 0.71 (0.8-2.0) mmol/l
Alkaline phosphatase 68 (<120) U/l
ASAT 25 (<40) U/l
ALAT 15 (<45) U/l
GT 14 (<35) U/l
Normal values are given between brackets. CRP = C-reactive protein;
ASAT = aspartate aminotranspeptidase; ALAT = alanine amino-
transpeptidase; GT = gamma glutamyl transpeptidase.
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Figure 1 Serum amylase (Y-axis) in time in the
absence or presence of TMP/SMX exposure
Since serum amylase was normal in the first episode of epigastric
pain, this episode is not shown in the figure. Time between episode
two and three is approximately two months. Day one of the second
episode represents the visit to the emergency department because
of epigastric pain. Day one of the third episode represents the day
of restarting TMP/SMX.
D I S C U S S I O N
Drugs are classified as having a definite relation with the
development of pancreatitis if there is a temporal relation-
ship between drug administration and the signs and
symptoms of pancreatitis or a positive response to direct
(re)challenge with the drug.7 Previous case reports have
demonstrated/suggested an association between pancreatitis
and TMP/SMX (table 1).1-6 Sulfamethoxazole is generally
held responsible since sulphonamide derivates have been
associated with pancreatitis while trimethoprim alone has
not.8,9 A definite causal relationship between sulfamethoxa-
zole administration and pancreatitis, shown by rechallenge,
has only been demonstrated in a few cases.1,8 The pancre-
atitis-inducing mechanism remains unclear. An allergic
reaction has been assumed.8
Here we report a patient who developed acute pancreatitis
after having taken TMP/SMX for many years as prophylaxis
for pyelonephritis. During her first episode of epigastric
pain, the diagnosis of acute pancreatitis was considered,
but based on her clinical condition and a normal serum
amylase level, measured four days after the first symptoms,
a diagnosis of gastric ulceration seemed more likely.
Retrospectively, it seems probable that our patient had
already suffered a bout of acute pancreatitis during that
episode. During her second episode of epigastric pain,
serum amylase levels were definitely elevated and acute
pancreatitis was diagnosed. Known causes of acute pan-
creatitis include alcohol abuse, cholelithiasis, hyperlipi-
daemia, hypercalcaemia, pancreatic trauma, viral infections
and drugs. Based on a negative history of alcohol abuse
and pancreatic trauma, normal values of liver enzymes,
triglycerides and calcium, and the absence of ulcers, bile
stones and other liver or bile duct abnormalities on a
plain abdominal X-ray, abdominal ultrasonography, gastro-
duodenoscopy and MRCP, all of the above-mentioned
causes could be excluded with the exception of drugs.
This is supported by the fact that discontinuation of TMP/
SMX treatment resulted in her symptoms disappearing
completely. However, a causal relationship was finally
confirmed when we observed a relapse of acute pancreatitis
within four days of restarting TMP/SMX because of adverse
effects to prophylaxis with ciprofloxacin. Since trimethoprim
alone has not been associated with acute pancreatitis, we
eventually decided to use trimethoprim as a prophylactic
drug for pyelonephritis.
The interval between starting the cotrimoxazole and the
onset of pancreatitis was long. For various drugs it is well
known that complications do not occur immediately after
the start of the drug therapy, as for instance for azathioprine.
In a recent review paper it was stated that ‘Cutaneous
reactions are hypersensitivity reactions and they usually
manifest immediately after exposure or re-exposure to the
drug, unlike other adverse reactions, which might only
manifest at high doses or after prolonged therapy’.10 The
absence of a rash in the patient presented in this paper
does not support the hypothesis of a hypersensitivity
reaction as the cause of the pancreatitis.
Our case is unique in that it demonstrates a definite causal
relationship between acute pancreatitis and TMP/SMX in
a patient who had been taking this antibiotic continuously
for more than 20 years. Based on this experience, we
advise that this medication is immediately discontinued if
a causal relationship with pancreatitis is highly suspected.
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C A S E  R E P O R T
A 73-year-old woman presented to the emergency department with progression of pain in the lower abdomen. The pain
developed two months earlier, following pneumonia treated with antibiotics. Initially, it was accompanied by a short
episode of diarrhoea and vomiting, which spontaneously resolved. She had a documented history of rheumatoid arthritis,
diabetes mellitus type 2, hypertension, hypercholesterolaemia, myocardial infarction and cholecystectomy.
On admission there were no other abdominal symptoms. She was only having one bowel motion a day with lactulose
intake. Her daily oral food intake was normal and there was no history of weight loss. Her rheumatoid arthritis has been
stable for years. She stopped smoking more than 20 years ago. Current medication consisted of insulin, prednisone,
a depot methylprednisolone every ten weeks, nitrazepam, acetylsalicylic acid, diclofenac, omeprazol, bumetanide,
metroprolol, folic acid and lactulose. Physical examination revealed a moderately ill patient with a blood pressure of
140/80 mmHg, a pulse rate of 85 beats/min and a body temperature of 37°C. On auscultation active bowel sounds were
heard. On palpation a localised tenderness in the lower abdomen, somewhat more pronounced in the right lower quadrant,
was found. Blood tests revealed 17.2 x 109 leucocytes (88% neutrophils, 8% monocytes, 4% monocytes), CRP 144 mg/l,
creatinine 69 mol/l, alkaline phosphate 146 U/l, ASAT 11 U/l, ALAT 22 U/l, GT 25 U/l, amylase 63 U/l, lactate 1.8 mmol/l
and glucose 15.1 mmol/l. The urine examination was normal, except for glucosuria. The gynaecological examination was
normal. A contrast-enhanced CT scan of the abdomen is presented in figures 1 and 2.
W H A T  I S  Y O U R  D I A G N O S I S ?
See page 285 for the answer to this photo quiz.
P H O T O  Q U I Z
A patient with prolonged vague pain in the
lower abdomen following a three-day period
with diarrhoea and vomiting
T.M. Bisseling1*, J.W. op den Akker2, M. Janssen1, S.P. Strijk2
Departments of 1Internal Medicine and 2Radiology, Radboud University Nijmegen Medical Centre,
Nijmegen, the Netherlands, e-mail: T.Bisseling@aig.umcn.nl, *corresponding author
Figure 1 A transverse contrast-enhanced abdominal
CT scan of the patient 
Figure 2 Coronal reconstruction of the abdominal 
CT scan
A B S T R A C T
Background: Global performance rating is frequently
used in clinical training despite its known psychometric
drawbacks. Inter-rater reliability is low in undergraduate
training but better in residency training, possibly because
residency offers more opportunities for supervision. The
low or moderate predictive validity of global performance
ratings in undergraduate and residency training may be due
to low or unknown reliability of both global performance
ratings and criterion measures. In an undergraduate
clerkship, we investigated whether reliability improves
when raters are more familiar with students’ work and
whether validity improves with increased reliability of the
predictor and criterion instrument.
Methods: Inter-rater reliability was determined in a clerk-
ship with more student-rater contacts than usual. The
in-training assessment programme of the clerkship that
immediately followed was used as the criterion measure
to determine predictive validity.
Results: With four ratings, inter-rater reliability was 0.41
and predictive validity was 0.32. Reliability was lower and
validity slightly higher than similar results published for
residency training.
Conclusion: Even with increased student-rater interaction,
the reliability and validity of global performance ratings
were too low to warrant the usage of global performance
ratings as individual assessment format. However, combined
with other assessment measures, global performance
ratings may lead to improved integral assessment.
K E Y W O R D S
Clerkship, disattenuation, global clinical performance rating,
inter-rater reliability, predictive validity
I N T R O D U C T I O N
Evaluation of clinical performance typically takes the form
of a global rating by a supervisor, halfway or at the end of
a clinical rotation, covering learners’ performance on a
number of clinically relevant competencies over a certain
period of time. Hereafter, we will refer to this type of rating
as global performance rating (GPR). Despite the availability
of new assessment methods, GPRs continue to be frequently
used in both undergraduate and residency training, most
probably due to the combined advantage of feasibility and
face validity (the assessed performance represents the
performance domain of interest). In undergraduate training,
GPRs are often the primary determinant of the final grade
a student receives at the end of a clerkship.1,2 Moreover,
despite measures to increase the reliability of GPRs, such
as rater training, in practice most assessors are not trained.
At best the items on a scale are anchored to descriptors of
criterion behaviour. In the last two decades several studies
have examined the reliability and validity of GPRs by
untrained assessors in both undergraduate and residency
training.
For inter-rater agreement among members of staff as a
measure of the reliability of GPRs in undergraduate training
the findings varied, with inter-rater agreement ranging
from 0.29-0.42.3,4 Studies performed in residency training
have consistently demonstrated higher inter-rater agreement
(0.79-0.87) than studies among undergraduate students.5-8
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S P E C I A L  R E P O R T
Global clinical performance rating, reliability
and validity in an undergraduate clerkship
H.E.M. Daelmans1*, H.H. van der Hem-Stokroos2, R.J.I. Hoogenboom3, 
A.J.J.A. Scherpbier4, C.D.A. Stehouwer5,6, C.P.M. van der Vleuten3
Departments of 1Skills Training, 2Surgery and 6Medicine, Vrije universiteit Medical Centre, Amsterdam, 
the Netherlands, tel.: +31 (0)20-444 80 31, fax: +31 (0)20-444 80 30, e-mail:
hem.daelmans@vumc.nl, 3Department of Educational Development and Research, 
4Faculty of Medicine/Institute for Medical Education, Maastricht University, the Netherlands,
5Department of Medicine, Maastricht University Hospital and Maastricht University, the Netherlands,
*corresponding author
A possible explanation for this difference may be that
clinical staff, who typically evaluate students’ and residents’
performance, generally have more opportunity to super-
vise the work of residents than that of students because
residency rotations last longer than clerkship rotations.9,10
Moreover, because residents treat patients, supervision of
residents is necessary to ensure the provision of appropri-
ate patient care. Staff members have a strong professional
stake in an adequate performance by residents, because
they may be held liable for adequate supervision.11
Assuming that the reliability of assessment benefits from
increased supervision, we designed a study in which we
measured inter-rater agreement on GPRs in a setting where
staff members supervised students’ work more frequently
than is customary in undergraduate clerkships. If our
assumption is correct, we would expect inter-rater agree-
ment in this setting to be moderate to quite high.
Studies have investigated both concurrent and predictive
validity of GPRs by untrained assessors. Both concurrent
and predictive validity indicate the extent to which GPRs
predict scores on a selected criterion that is not directly
measured by the assessment but that is assumed to be
parallel. For concurrent validity the criterion measurement
is performed at the same time, for predictive validity it is
performed at some point in the future. Concurrent validity
has been studied in both undergraduate and residency
training by correlating GPRs with more objective perform-
ance measures for the same training period, such as written
examinations, OSCEs or simulated patient exams.6,12-14
Correlations ranged from 0.19 to 0.33 for undergraduate
training and from 0.29 to 0.56 for residency training.
Fewer studies have addressed the predictive validity of
GPRs. In undergraduate training predictive validity has
been determined by comparing GPRs of student perfor-
mance in different rotations with GPRs of end-of-clerkship
performance or of performance in residency training.
Predictive validity ranged from 0.17 to 0.44.12,15 Callahan
examined the predictive validity of GPRs in clerkships for
the results on United States Medical Licensing Examinations
(USMLE) steps 2 and 3. The maximum predictive validity
was 0.29 for USMLE step 2 and for USMLE step 3 it was
0.20.15 In residency training the predictive validity of GPRs
for performance at in-training and American Board of
Internal Medicine certification exams was reported to be
moderate for overall competence (0.19) and for specific
competencies on a global performance rating scale (ranging
from 0.11 to 0.41).8,16 The validity coefficients reported in
these studies suffered from attenuation, i.e. low or unknown
reliabilities in predictor and criterion variables introduce
inaccuracy into the calculation. When a measurement
error is present in one or both of the variables that are
being correlated, the correlation coefficient that is obtained
will be attenuated. This implies that the observed correlation
coefficient between less than perfectly reliable scores will
tend to underestimate the true level of co-variation between
the predictor and criterion variables.17 Therefore, if the
reliability of either the predictor or the criterion variables
is low, validity coefficients will also be low. This effect
might have been even stronger in studies in undergraduate
training settings, where the reliability of global ratings
was typically low and the reliability of the criterion variable
mostly unknown. That is why we considered it worthwhile
to examine the predictive validity of GPRs in undergraduate
training using a criterion variable of known and acceptable
reliability. If staff members have more opportunities to
supervise students’ performance the reliability of GPRs in
undergraduate medical training might benefit.
We thus sought to answer the following research questions:
what is the reliability of GPRs in an undergraduate clerkship
with increased rater-student interactions? And, because of
the inaccuracy in validity estimates of GPRs due to the
low or unknown reliabilities of predictor and criterion
variables (attenuation): what is the validity of GPRs when
the reliabilities of both predictor and criterion variables
are assumed to be perfect (disattenuation correction)?
We addressed the research questions by determining the
inter-rater agreement for GPRs in an undergraduate
clerkship with extensive interaction (detailed below) of
staff members (raters) and students. These GPRs were
then compared with a valid and reliable performance
measure for the competencies demonstrated by the same
students in the next clerkship that immediately followed,
with less student-staff interaction. The performance
measure used in the second rotation was the overall score
on an in-training assessment programme (ITA) consisting
of several assessments of clinical competence.
M A T E R I A L S  A N D  M E T H O D S
Educational background
At the Vrije Universiteit Medical Centre (VU Medical Centre),
Amsterdam, the Netherlands, four years of preclinical
medical education are followed by two years of rotations
in the major clinical disciplines. The clinical phase starts
in year 5 with a three-week introductory clerkship in
which the students are closely supervised by clinical staff.
The students’ main tasks are history taking and physical
examination, medical record writing and practising skills
in pathophysiological thinking and clinical reasoning in
structured discussions both in groups supervised by a
member of staff and in writing. Staff members are sched-
uled to supervise the group discussion, discuss the medical
records and observe (parts of) history taking and physical
examination. Every day a different staff member supervises
the students in their daily structured group discussion,
which lasts about an hour. The supervisor asks several
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students to elaborate on their findings, interpret data,
formulate differential diagnoses and propose additional
investigations. Over the course of the clerkship, students
are supervised twice by a member of staff while performing
a (scheduled) complete patient interview and physical
examination. Afterwards student and staff member discuss
the student’s performance. For morning and evening
reports, radiology meetings, interdisciplinary meetings et
cetera, students are not linked to residents but to members
of staff, who are thus more focussed on students’ contri-
butions. In most cases, a student is supervised by six to
seven members of staff during the three-week rotation. At
the end of the three weeks, a staff member to whom this
task has been assigned determines a GPR for the student’s
performance during the rotation. Next, the students move
on to the ten-week internal medicine rotation in the VU
Medical Centre or in one of the affiliated hospitals. This
rotation is scheduled immediately after the introductory
clerkship. In this rotation the students are usually super-
vised by residents instead of members of staff during
student-patient interactions and for medical records. This
rotation involves more participation by the students in
day-to-day clinical practice, including multidisciplinary
meetings and on call duties. In order to better monitor
students’ performance in the internal medicine clerkship,
a programme of systematic observation and documentation
of students’ actual performance (detailed below) has been
introduced in the rotation in the VU Medical Centre.
Global clinical performance rating
Eight supervisors of the introductory clinical rotation were
approached during a staff meeting and asked to participate in
the study. Participation entailed giving a global performance
rating on a five-point Likert scale (1 = fail, 2 = borderline, 
3 = pass, 4 = high pass, 5 = excellent) for every student
doing the rotation in the study period. The raters received
a brief description to be used in rating students’ perform-
ance. The description mainly focused on the comparison
of the student’s performance with that of an average student
in his/her first three weeks of clinical rotation. On a student’s
last day of this rotation, the members of staff received a
form together with a scanned picture of the student con-
cerned. The members of staff who had interacted with
the student were asked to complete and return the form.
The members of staff who had not supervised the student
could return the form without filling it in. The entire pro-
cedure was computerised. We used a single-item rating
(global performance) to preclude the use by raters of only
one or two items (dimensions of performance) of a larger
scale to judge global performance.5,6,16,18,19 Each participating
staff member was asked to complete one evaluation form
for each student during the study period. In this way
students could receive a maximum of eight GPRs from
different examiners.
In-training assessment
All students proceed from the introductory rotation to the
internal medicine rotation. In the internal medicine rotation
in the VU Medical Centre a fully integrated ITA programme
is used. ITA implies systematic observation and documen-
tation of the learners’ actual performance using several
formats.20 ITA in undergraduate clinical training has
been described as a feasible assessment format that has
reasonable reliability and good content validity.20-22 The
ITA programme used in this study consisted of observation
and documentation of students’ actual performance in
five test formats.22 A minimum frequency per student
over the entire clerkship was specified for each test format,
resulting in a required total of 19 assessments: three single-
sample formats (student-patient encounter, critical appraisal
session and case presentation) and two multiple-sample
formats (12 case write-ups and four structured long
cases). The student-patient encounter, critical appraisal
session, case presentation and structured long cases were
assessed by staff and the case write-ups by residents.
All tests were rated on the five-point Likert scale and an
overall score was obtained by calculating the mean of the
scores and rounding it off to the nearest integer (1-5). The
assessors of the ITA programme were not specifically
informed about the current study.
Subjects: student participants
From April 2001 to October 2002, 91 students received
global ratings of their performance in the introductory
clerkship. We collected ITA scores for 48 of these 91
students. These 48 students did the subsequent ten-week
internal medicine rotation in the VU Medical Centre,
whereas the other students went to affiliated hospitals,
where the ITA programme had not yet been implemented.
A t-test on the means of the GPRs showed no differences
between the GPRs of the students participating in the
study and the students assigned to the affiliated hospitals.
Data analysis
First we counted the total number of GPRs per student.
For further calculations we used the balanced dataset of
the group of students for whom at least four GPRs were
available.23 For the analysis we used random samples of
four GPRs per student.
We calculated means and standard deviations for the GPRs.
Inter-rater reliability was estimated based on the general-
isability theory. We used a one-facet design with raters (or
GPRs) nested within persons (students) to estimate variance
components. Subsequently, reliability coefficients, i.e.
dependability coefficients, were calculated as a function
of the number of examiners (or GPRs). In the clerkship
studied, each member of staff supervised students in two
to three group discussions and most probably several
Daelmans, et al. Global clinical performance rating.
J U L Y - A U G U S T  2 0 0 5 ,  V O L .  6 3 ,  N O .  7
281
times during reports and meetings. Only two members of
staff witnessed complete student-patient contacts (interview
and physical examination). As a result, these two staff
members may have developed significantly different
judgements than did other staff members. However, the
fact that different selections of four members of staff did
not yield significantly different ratings suggests that this
was not the case.
We calculated means and standard deviations of the ITA
scores. A similar generalisability design was used to estimate
the reliability of the ITA programme, with observations
across test formats nested within students.
The predictive validity of the GPRs was determined by
correlating the mean GPR with the mean ITA score. We
estimated the disattenuated correlation (the estimated
correlation when both predictor and criterion measures have
perfect reliability) using the reliability coefficient of the GPRs
with four raters and the reliability of the ITA programme.
R E S U L T S
Of the 91 students whose performance was rated in the
introductory clerkship, 87 received four or more GPRs
(table 1). Four students were rated by fewer than four staff
members. Each of the eight members of staff who partici-
pated in the study contributed to the GPRs throughout
the duration of the study. Having had no interaction with
the student, holidays and illness were the main reasons
given by staff members for not having witnessed a student’s
performance and thus being unable to provide a GPR.
The mean GPR was 3.19 (SD 0.37). Inter-rater reliability
with four GPRs per student was 0.41 (n=87). Twenty-five
GPRs per student would be needed to reach sufficient
reliability (0.8) (table 2).
Means and standard deviations of the different ITAs ranged
from 3.61 (SD 0.65) for case write-ups to 4.35 (SD 0.65)
for case presentations (table 3).
The reliability of the ITA programme was 0.71. The observed
predictive validity of the GPRs for the ITA programme was
0.32 (p<0.05) and the disattenuated predictive validity
was 0.59.
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Table 1 The number of global performance ratings
(GPRs) per student
Number of GPRs 2 3 4 5 6 7 8
Number of students 1 3 13 30 16 23 5
Table 2 Reliability coefficients as a function of the
number of examiners or global performance ratings
(GPRs)
Number of GPRs 4 6 10 25
Reliability coefficient 0.41 0.51 0.63 0.81
Table 3 Mean scores (standard deviations; SD) for the dif-
ferent tests in the in-training assessment (ITA) programme
ITA Mean (SD)
Student-patient encounter 3.70 (.70)
Critical appraisal session 4.00 (.67)
Case presentation 4.35 (.65)
Write-up 3.61 (.65)-4.04 (.71)
Structured long case 4.00 (.67)-4.26 (.63)
D I S C U S S I O N
Global ratings have some well-known disadvantages. They
are often only given at the end of a rotation when assessors
may have forgotten details of student’s performance. In
addition, they may be biased due to a halo effect, i.e. the
phenomenon that an impression created by a student’s
good or poor performance in one area affects assessors’
judgements of that student’s performance in another area.24
In the introductory clerkship, we could easily have used
structured assessment with rating forms, such as in-training
assessment. However, we purposely used global ratings,
because in this study we set out to investigate the possibility
of improving the reliability and validity of such ratings, as
they continue to be much used in undergraduate and
graduate training. With improved reliability and validity,
global ratings could make a truly positive contribution to
assessment of clinical performance, the more so since
they can cover more competencies than assessment formats
focused on specific items.25
We investigated the reliability and the predictive validity of
GPRs in undergraduate training. We studied the reliability
of GPRs in an introductory clerkship where the members
of staff who rated the students supervised students’ per-
formance more frequently than is customary in under-
graduate clerkships. We expected that this would yield a
better, i.e. moderate to high, reliability than is generally
reported for GPRs in undergraduate clinical training.
We observed an inter-rater reliability of 0.41, which is
comparable with the literature on undergraduate inter-rater
agreement. We speculate that the potentially positive
influence of increased supervision of students’ clinical work
by staff may have been mitigated by the limited duration
of the clerkship as compared with residency rotations.26
A relatively shorter period during which staff are in a posi-
tion to supervise students may lead to a correspondingly
diminished accuracy of the perceived levels of students’
performance. Hence increased supervision did not result
in improved reliability. Furthermore, reliability may have
(slightly) suffered on account of staff not having participated
in assessment training before this study was conducted.27,28
The results showed that 25 GPRs from different examiners
would be needed to achieve adequate reliability. Other
studies have yielded estimates of between 7 and 14 ratings
to attain a reliability of 0.80.5,29,30 However, the assessment
formats on which the GPRs in those studies were based
included aspects that might potentially improve reliability,
such as a long duration of the student-staff work relation-
ship (up to one year), a highly detailed description of the
behaviour associated with the low and high scale points
on the rating scale and raters who were better acquainted
with students’ performance (e.g. resident ratings). We
suspect that more ratings will be needed to reach acceptable
reliability in undergraduate settings, where the working
relationship of staff and students lasts only a short time
and raters thus witness less of the students’ work and
have to judge performance without guidance from concrete
descriptions of the behaviours corresponding to the different
scale points.
The validity measure derived from the predictive validity
of the GPRs for the scores on the ITA programme in the
subsequent clerkship was 0.32. Although slightly higher
than the predictive validity reported for overall competence
in studies in both undergraduate and residency training,
it is still quite low.8,15 The GPRs in this study were based
on staff members’ evaluations of students at the end of a
three-week rotation. Despite frequent student-staff inter-
action in these three weeks, details of the interactions can
be lost quite quickly.31,32 In contrast, the evaluations in the
ITA programme were recorded immediately after the
activity or behaviour that was evaluated and according to
a checklist. Despite the more than usually intensive inter-
action between staff and students in the initial clerkship,
the fact that the GPRs were based on less detailed infor-
mation about students’ clinical performance than the ITA
scores may offer an explanation for the low predictive
validity of the GPRs. Disattenuated predictive validity was
0.59, however, which is much higher. Our findings implicate
that GPRs, despite being based on less detailed information,
can still make a positive contribution to the evaluation of
students’ performance. In a recently published study,
Kreiter and Ferguson found comparable disattenuated
predictive validity when they compared global ratings of
clinical clerkship performance with former measures of
physical examination performance provided by simulated
patients (SP) using ratings and checklists, and with SP
ratings of rapport and communication.33 They conclude
that measures of skills by global ratings are correlated
with other clinical performance measures and discuss
that more studies of this topic are needed to conclude that
global ratings make a positive contribution to students’
evaluation and thus contributes to the conclusion that global
rating can positively contribute to students’ evaluation.
The evidence in our study points in the same direction.
This study has one major drawback. We compared our
findings to findings in the literature and not to those of a
control group. The circumstances in which research in
the presented literature was performed were certainly
different from the circumstances of our study. However,
it was practically not feasible to have a control group in
the same clerkship at the same time due to staff shortage
and the practical impossibility to have two educational
programmes performed by the same members of staff
during the same period of time.
Our results indicate that even when conditions in an
undergraduate rotation are positively manipulated, reliability
and validity of GPRs remain low. However, the reliability
and validity we reached were not lower than those found
for other assessment formats performed over a short testing
time.34,35 This means that GPRs can contribute to the
assessment of undergraduate students’ clinical competencies
as long as they are sampled on many occasions and by
many assessors. Nevertheless, sufficient reliability and
validity are likely to be hard to achieve. In a recent review,
Williams et al. concluded that GPRs by themselves were an
insufficient measure of students’ clinical competence, even
though they might be an important source of information
about it.36 These authors recommended that GPRs should
be supplemented with ratings of students’ performance in
standardised clinical encounters and assessment protocols.
The results of our study point to a similar recommendation,
i.e. to combine GPRs with more specific and reliable
assessment formats, such as the ITA programme in this
study, to arrive at an integrated assessment programme.
Further studies will have to examine whether such an
assessment programme can provide reliable and valid
measures of students’ competencies.
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D I A G N O S I S
The abdominal contrast-enhanced CT scan shows mild diverticulosis of the sigmoid (solid arrows, figure 1), with infiltration
of the surrounding mesenteric fat (arrowheads, figure 1) extending along the inferior mesenteric vein (open arrow, figure 1).
The wall of the inferior mesenteric vein is thickened and the lumen shows filling defects (arrowheads, figure 2) consistent with
thrombosis. The splenic and portal veins are open, and there are no signs of appendicitis. These findings are very con-
sistent with a thrombophlebitis of the inferior mesenteric vein complicating a mild sigmoid diverticulitis.
Thrombotic events of the mesenteric veins lack specific clinical symptoms and laboratory data. Mesenteric vein thrombosis
is diagnosed in 5 to 15% of all mesenteric ischaemic events,1 usually in the superior mesenteric vein. In about 75% of
the patients it occurs secondary to abdominal inflammation, cancer, coagulation disorders, recent abdominal surgery, or
cirrhosis in portal hypertension.1,2
Thrombophlebitis of the inferior mesenteric vein secondary to diverticulitis occurs infrequently,3 and may be complicated
by sepsis and intrahepatic abscesses. CT imaging helps to diagnose this complication at an early stage and can significantly
improve the previously reported high mortality and morbidity rates associated with this condition. Conservative therapy
with antibiotics, which target Gram-negative bacilli, anaerobes and enterococci, can lead to resolution of the thrombosis.4
Although the effect remains controversial, in most cases anticoagulant therapy is started. Elective surgery may be performed
to eradicate the primary inflammatory process when antibiotic therapy fails.
Immediately after admission, this patient was started on anticoagulant therapy. Because the abdominal pain persisted and
the CRP concentration rose to 246 mg/ml, intravenous antibiotic therapy was started within 48 hours, resulting in a
clinical improvement. Blood cultures obtained on the first and second day of admission were negative. After one week
the antibiotics amoxicillin/clavulanic acid were continued orally and the patient was discharged. At follow-up the patient
had made a full recovery, laboratory parameters normalised, and the CT scan no longer showed abnormalities. 
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